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RÉSUMÉ 
 
Chez Saccharomyces cerevisiae, les souches mutantes pour Rrd1, une 
protéine qui possède une activité de peptidyl prolyl cis/trans isomérase, montrent une 
résistance marquée à la rapamycine et sont sensibles au 4-nitroquinoline 1-oxide, un 
agent causant des dommages à l’ADN. PTPA, l’homologue de Rrd1 chez les 
mammifères, est reconnu en tant qu’activateur de protéine phosphatase 2A. Notre 
laboratoire a précédemment démontré que la surexpression de PTPA mène à 
l’apoptose de façon indépendante des protéines phosphatase 2A. La fonction 
moléculaire de Rrd1/PTPA était encore largement inconnue au départ de mon projet 
de doctorat. 
Mes recherches ont d’abord montré que Rrd1 est associé à la chromatine ainsi 
qu’à l’ARN polymérase II. L’analyse in vitro et in vivo par dichroïsme circulaire a 
révélé que Rrd1 est responsable de changements au niveau de la structure du domaine 
C-terminal de la grande sous-unité de l’ARN polymérase II, Rpb1, en réponse à la 
rapamycine et au 4-nitroquinoline 1-oxide. Nous avons également démontré que Rrd1 
est requis pour modifier l’occupation de l’ARN polymérase II sur des gènes 
répondant à un traitement à la rapamycine. Finalement, nous avons montré que suite à 
un traitement avec la rapamycine, Rrd1 médie la dégradation de l’ARN polymérase II 
et que ce mécanisme est indépendant de l’ubiquitine. 
La dernière partie de mon projet était d’acquérir une meilleure connaissance 
de la fonction de PTPA, l’homologue de Rrd1 chez les mammifères. Nos résultats 
montrent que le «knockdown» de PTPA n’affecte pas la sensibilité des cellules à 
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différentes drogues telles que la rapamycine, le 4-nitroquinoline 1-oxide ou le 
peroxyde d’hydrogène (H2O2). Nous avons également tenté d’identifier des 
partenaires protéiques pour PTPA grâce à la méthode TAP, mais nous ne sommes pas 
parvenus à identifier de partenaires stables. Nous avons démontré que la 
surexpression de la protéine PTPA catalytiquement inactive n’induisait pas 
l’apoptose indiquant que l’activité de PTPA est requise pour produire cet effet. 
Finalement, nous avons tenté d’étudier PTPA dans un modèle de souris. Dans un 
premier lieu, nous avons déterminé que PTPA était exprimé surtout au niveau des 
tissus suivants : la moelle osseuse, le thymus et le cerveau. Nous avons également 
généré avec succès plusieurs souris chimères dans le but de créer une souris 
«knockout» pour PTPA, mais l’allèle mutante ne s’est pas transférée au niveau des 
cellules germinales. 
Mes résultats ainsi que ceux obtenus par mon laboratoire sur la levure 
suggèrent un rôle général pour Rrd1 au niveau de la régulation des gènes. La question 
demeure toujours toutefois à savoir si PTPA peut effectuer un rôle similaire chez les 
mammifères et une vision différente pour déterminer la fonction de cette protéine sera 
requise pour adresser adéquatement cette question dans le futur. 
 
Mots clés : transcription, RNA polymérase II, Rrd1, PTPA, PP2A, isomérisation 
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ABSTRACT 
 
In Saccharomyces cerevisiae, mutants devoid of Rrd1, a protein possessing in 
vitro peptidyl prolyl cis/trans isomerase activity, display striking resistance to 
rapamycin and show sensitivity to the DNA damaging agent 4-nitroquinoline 1-
oxide. PTPA, the mammalian homolog of Rrd1, has been shown to activate protein 
phosphatase 2A. Our laboratory previously found that overexpression of PTPA leads 
to apoptosis independently of PP2A. At the outset of my thesis work, the molecular 
function of Rrd1/PTPA was largely unknown. 
My work has shown that Rrd1 is associated with the chromatin and interacts 
with RNA polymerase II. In vitro and in vivo analysis with circular dichroism 
revealed that Rrd1 mediates structural changes of the C-terminal domain of the large 
subunit of RNA pol II, Rpb1, in response to rapamycin and 4-nitroquinoline 1-oxide. 
Consistent with this, we demonstrated that Rrd1 is required to alter RNA pol II 
occupancy on rapamycin responsive genes. We also showed that upon rapamycin 
exposure Rrd1 mediates the degradation of RNA polymerase II and that this 
mechanism is ubiquitin-independent.  
Another part of my work was to gain insight into the function of PTPA, the 
mammalian counterpart of Rrd1. PTPA knockdown did not affect sensitivity to 
rapamycin, 4-nitroquinoline 1-oxide or H2O2. We also attempted to find protein 
interaction partners for PTPA using tandem affinity purification, but no stable 
partners for PTPA were found. We also demonstrated that overexpression of a 
catalytically inactive PTPA mutant did not induce apoptosis, indicating that PTPA 
activity is required to produce this effect. Finally, we attempted to study PTPA in a 
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mouse model. We first determined that PTPA was expressed in a tissue-specific 
manner and was most abundant in bone marrow, thymus and brain. We pursued 
creation of a knockout mouse and successfully generated chimeras, but the mutated 
allele was not transmitted to the germline.  
My data and other data from our laboratory regarding the yeast work suggest a 
general role for Rrd1 in regulation of gene transcription. Whether PTPA has a similar 
function in mammalian cells remains unknown, and a different vision of what the 
protein does in mammalian cells will be required to adequately address this question 
in the future.   
 
Keywords: transcription, RNA pol II, Rrd1, PTPA, PP2A, isomerisation 
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CHAPTER 1 
 
 
 
 
Litterature review: Transcription, cell growth and Rrd1/PTPA 
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1 INTRODUCTION 
 
According to the Canadian Cancer Society, cancer represents the leading 
cause of death in Canada since 2007. Studying cell metabolism is crucial both for a 
better understanding of the disease and for generating possible treatments. Cancer is a 
very complex disease and many factors can contribute to its development. Lifestyle, 
environmental events and heredity are all possible causes for cancer although it is 
often a combination of multiple factors. In order to circumvent these events, cells 
have developed a plethora of mechanisms to ensure regulated proliferation and 
growth and to maintain genomic integrity. 
Deregulation of two classes of genes, named oncogenes and tumor suppressor 
genes, can lead to the onset of cancer.  Inappropriate upregulation of oncogenes 
induces unregulated cell proliferation, leading to cancer. For example, activating 
mutations of the proto-oncogene Ras, a gene normally quiescent, are found in about 
20% of all tumours and lead to uncontrolled growth of the cells [1, 2]. Current drugs 
used in cancer treatment target these genes or their products [3, 4].  Tumor suppressor 
genes function in pathways that protect against mutation or unregulated growth.  
Inactivating mutations in these genes can lead to tumorigenesis.  Examples of tumor 
suppressors include genes involved in DNA repair, apoptosis, and transcription 
factors activated by cellular stress that induce cell cycle arrest in order to ensure DNA 
integrity [5]. Half of all cancers involve alteration of the important and best described 
tumor suppressor gene p53 [6]. Mutations in oncogenes and tumor suppressor genes 
arise when DNA damage is not repaired correctly, leading to irreversible mutations 
that alter protein function and regulation.  Two categories of sources can cause DNA 
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damage: exogenous and endogenous. Exogenous DNA damaging agents include 
ultraviolet (UV) light from the sun, radiation such as x-rays or γ-rays, viruses, toxins 
or chemicals, and the main endogenous source is reactive oxygen species (ROS) [7, 
8]. Cells have developed specific mechanisms to repair each type of DNA lesion in 
order to prevent carcinogenesis. Single-strand damage (SSD) is characterized by 
damage on only one strand of the DNA double helix [9]. Excision repair mechanisms 
use the intact strand as a template to repair the defective one. In base excision repair 
(BER), a damaged base is removed by a DNA glycosylase, resulting in an 
apurinic/apyrimidinic (AP)-site that is cleaved by an AP-endonuclease. Synthesis of 
the DNA is performed by a DNA polymerase and a DNA ligase seals the nick to 
complete repair [10]. Nucleotide excision repair (NER) repairs lesions caused by 
ultraviolet light and can be divided into global genome NER (GG-NER) or 
transcription-coupled repair (TC-NER). These two pathways differ in how the lesion 
is recognized, but share the later steps  in which the lesion is excised and the resulting 
gap is filled [11]. Finally, mismatch repair (MMR) recognizes erroneous insertion, 
deletion or mis-incorporation of bases and repairs the wrong nucleotides with the 
correct ones [12]. 
Double-strand breaks (DSBs) are lesions of both strands of the DNA and can 
be repaired using either non-homologous end-joining (NHEJ) or homologous 
recombination (HR) [13]. In NHEJ, cells directly rejoin both ends of the break.  This 
pathway is mostly used before DNA replication, when a sister chromatid is not 
available to serve as a template [14, 15]. On the other hand, HR uses the identical 
sequence from replication as a template to accurately repair the break.  
4 
 
Better understanding of proteins involved in the oxidative stress response is 
important for prevention of cancer and other diseases. Oxidative stress is caused by 
an imbalance between antioxidants and ROS such as free radicals or peroxides. Free 
radicals are unstable molecules with an unpaired electron that will rapidly react with 
proteins, lipids or DNA. Several types of DNA damage result from ROS including 
oxidized bases and strand breaks [7]. A main objective of our lab was to discover new 
genes important in the oxidative stress response. This was investigated in the budding 
yeast Saccharomyces cerevisiae, since this eukaryotic cell is genetically easy to 
manipulate. Homology between key proteins from yeast and mammalian cells also 
strengthens the notion of using yeast as model [16]. 
A yeast screen revealed that cells with a mutation in the RRD1 gene were 
hypersensitive to 4-nitroquinoline 1-oxide (4-NQO) but resistant to ultraviolet C 
(UVC). 4-NQO causes a variety of DNA damage such as bulky adducts and oxidative 
stress. The metabolic activated form 4-hydroxyaminoquinoline interacts with DNA to 
form stable quinoline-purine monoadducts repaired by NER [17-19]. UVC (280-100 
nm) engender bulky adducts on DNA [20] also repaired by NER [21]. Further 
characterization of the rrd1 deletion in different genetic backgrounds showed the 
same phenotype [22]. rrd1Δ mutants are sensitive to 4-NQO [22, 23], vanadate, 
cycloheximide, ketoconazole and high concentration of Ca2+, they are resistant to 
caffeine [24] and show defect in cell cycle progression and morphology [25]. 
Surprisingly, rrd1Δ mutant cells were later characterized to be resistant to rapamycin, 
a drug that inhibits the Target of rapamycin (TOR) signalling pathway (discussed in 
detail below) [24]. Our lab became interested in understanding RRD1 function in the 
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cell since it seemed important for both genomic integrity and cell growth. The first 
chapter of my thesis will review literature on RRD1 and related topics important for 
understanding its function in the cell. 
 
1.1 RAPAMYCIN AND TOR 
 
In Saccharomyces cerevisiae, rrd1Δ mutants are resistant to rapamycin, hence 
the gene name rapamycin resistant deletion 1 [24]. Rapamycin treatment is known to 
mimic starvation conditions in yeast by inhibiting the master kinase Target of 
Rapamycin (TOR). Genome array studies have revealed that expression of multiple 
genes is altered by rapamycin treatment, including repression of ribosomal genes and 
activation of nitrogen source utilization genes [26].  
 
1.1.1 Rapamycin 
 
Rapamycin is a bacterial product found on Easter Island that interacts with the 
isomerase FKPB12 (Fpr1 in S. cerevisiae) to inhibit TOR [27]. Rapamycin is widely 
used in transplant therapy since it inhibits the proliferation of T cells. Rapamycin has 
several effects on the immune system such as inhibiting type I interferon production 
in plasmacytoid dentritic cells [28], modulation of T cell trafficking [29] and 
regulating Foxp3 expression in regulatory T cells [30]. On the other hand, recent 
studies have snown that rapamycin can increase the generation of CD8+ memory T 
cells [31-33]. Late administration of rapamycin can increase lifespan in mice [34]. 
Understanding the exact mechanism of TOR inactivation in T cells represents the 
next challenge of future work.  
6 
 
Rapamycin has also been used as an anticancer treatment acting as a cytostatic 
agent on several cancer cell lines. It can also sensitize cells to apoptosis when treated 
in combination with other chemotherapeutics agents [35-37]. In past years, analogs of 
rapamycin have been synthesized to circumvent the poor water solubility and low 
bioavailability of rapamycin [38]. New molecules such as temsirolimus and 
everolimus have recently been approved by the Food and Drug Administration (FDA) 
to treat advanced/metastatic renal cell carcinoma [39, 40].    
 
1.1.2 TOR  
 
The target of rapamycin (TOR) is a conserved Ser/Thr protein kinase which 
represents the catalytic activity of two complexes in the cell, TOR complex 1 
(TORC1) and TOR complex 2 (TORC2) [41, 42]. The two complexes are formed of 
distinct and shared proteins and are responsible for regulating cellular processes in 
response to the environment. In mammalian cells, one TOR gene is present whereas 
in yeast Tor1 and Tor2 form TORC1 and TORC2 respectively [42, 43]. In 
mammalian cells, acute treatment with rapamycin inhibits mTORC1 only [27] 
through inhibition of its interaction with Raptor (regulatory associated protein of 
mTOR) [44]. In sustained treatment, both mTORC1 and mTORC2 are inhibited.  
 
1.1.3 Yeast TOR 
 
In yeast, TOR is a large protein present in two distinctive complexes. The 
TOR complex 1 (TORC1) includes Tor1 or Tor2, the scaffolding protein kontroller of 
growth 1 (Kog1) and the nutrient sensitive permease sorting factor Lst8 [45, 46]. On 
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the other hand, the TOR complex 2 (TORC2) includes Tor2, Avo1 (adheres 
voraciously), Avo2, Avo3 and Lst8 [47]. 
The TOR signalling pathway responds to nutrients such as carbon or nitrogen 
in order to promote cell growth [48]. TOR regulates gene expression depending on 
the availability of the nitrogen source. For example, in the presence of poor nitrogen 
sources such as urea or proline, a subset of genes involved in processing these 
sources are upregulated following inactivation of TOR [49]. Treatments with 
rapamycin or inhibition of TOR proteins results in reduced ribosome biogenesis, 
upregulation of autophagy, transcriptional modifications and increased mRNA 
turnover [45]. TORC2 regulates the cell-cycle-dependent polarization of the actin 
cytoskeleton, and this function of TORC2 is rapamycin-insensitive [50].  
Both yeast Tor1 and Tor2 upregulate protein synthesis through activation of 
the translation initiation factor eIF4E as well as through transcriptional activation of 
ribosomal proteins. Inhibition of autophagy mediated by TOR phosphorylation of 
Apg1 is a mechanism to promote protein stability [51]. TOR also controls protein 
ubiquitylation by keeping nitrogen permease reactivator 1 (Npr1) in an inactive form 
[52]. The function of Npr1 is to stabilize plasma membrane amino acid transporters 
such as Bap2 [53], Mep2 [54], Tat2 [52] or Gap1 [55] against ubiquitylation-
dependent degradation. Finally, TOR is involved in regulating transcription through 
the inhibition of starvation specific genes. For example, TOR phosphorylates the 
GATA-type transcription factor Gln3 in order to maintain it in the cytoplasm. When 
TOR is inhibited, during rapamycin treatment or starvation conditions, 
unphosphorylated Gln3 translocates to the nucleus and activates the transcription of 
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genes involved in the metabolism of secondary nitrogen sources [26, 56]. TOR also 
inhibits general stress transcription factors by keeping them in the cytoplasm, such as 
the multicopy suppressor of SNF1 mutation 2-4 (Msn2 and Msn4) [57] and the 
heterodimeric retrograde regulation 1-3 (Rtg1-Rtg3) [58].   
TOR is important for the rapid regulation of a variety of protein phosphatase 
2A (PP2A) complexes. The type 2A associated protein-42kDa (Tap42) binds to Sit4 
phosphatase, a PP2A-related catalytic subunit in order to inhibit the 
dephosphorylation of both Npr1 and Gln3. The interaction between Tap42 and Sit4 is 
promoted by TOR phosphorylation of Tap42-interacting protein (Tip41). Treatment 
with rapamycin or inhibition of TOR leads to inactivation of Tip41, resulting in its 
binding to Tap42, which releases Sit4. Free Sit4 is then able to dephosphorylate 
transcription factors as well as Tip41, creating a fast response to stress conditions 
[59]. Our lab and others have shown that Rrd1 interacts with Sit4 phosphatase, and 
this interaction will be discussed in a later section [23, 60].  
 
1.1.4 Mammalian TORC composition 
 
In mammalian cells, both TOR complexes contain mTOR, mLST8/GβL and 
deptor [41, 42]. Deptor acts as an inhibitor of both mTORC1 and mTORC2 [61, 62], 
whereas mLST8/GβL binds to the mTOR kinase domain [63]. Raptor, a scaffold 
protein that links mTOR kinase to mTORC1 components [64], and PRAS40, an 
inhibitor or competitive substrate of mTORC1, are both specific to the mTORC1 
complex. On the other hand, Rictor (rapamycin-insensitive companion of mTOR) and 
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mSin1, which are important for mTORC2 assembly and signaling and PRR5/protor, 
are part of the mTORC2 complex [65]. 
 
1.1.4.1 mTORC1 
 
Anabolism is promoted through integration of both extra- and intracellular 
signals by the mTORC1. Nutrients and growth factors modulate mTORC1 activity in 
order to increase protein synthesis, cell growth, cell proliferation and cell metabolism 
[66]. Inactivation of mTORC1 leads to macroautophagy, or the degradation of cell 
proteins or organelles into amino acids or simple molecules [67]. 
 Growth factors signal through phosphatidylinositol 3-kinase (PI3K) to activate 
phosphoinositide-dependent kinase 1 (PDK1), leading to phosphorylation of Akt and 
subsequent inhibitory phosphorylation of the Tuberous Sclerosis Complex (TSC) 
(including TSC1 and TSC2). TSC2 contains a GTPase-activating protein [31] and has 
been shown to stimulate the Ras homologue enriched in brain (Rheb). TSC1 
stabilizes the TSC2 protein [68]. Inactivation of TSC complex allows the GTP-bound 
form of Rheb to interact and activate mTORC1 [69]. Amino acids, such as leucine, 
also activate mTORC1 through Rag proteins. These proteins bind to raptor and 
promote the interaction between Rheb and mTORC1 [70].   
Finally, mTORC1 is important for ribosomal protein synthesis [71]. The 
ribosomal S6 kinase 1 (S6K1) can be phosphorylated on Thr389 and the eukaryotic 
initiation factor 4E binding protein 1(4EBP1) can be phosphorylated on multiple sites 
(Thr37/46, Thr70 and Ser65) by mTORC1 kinase activity to promote cell growth and 
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proliferation. mTOR activation is usually measured by assaying these downstream 
substrates [72]. 
 
1.1.4.2 mTORC2 
 
The main substrate of mTORC2 is the serine/threonine protein kinase Akt, 
which promotes cell proliferation, survival and migration [73]. It is interesting that 
Akt regulation is both upstream (mTORC1) and downstream (mTORC2) of mTOR 
[41]. mTORC2 activates Akt through phosphorylation on serine 473 which allow the 
kinase to phosphorylate other substrate such as mTORC1 [74]. mTORC2 is also 
known for controlling actin cytoskeleton organization during cell growth through the 
activation of protein kinase C α (PKC-α) [75, 76].  
 
1.1.5 Rrd1 and TOR 
 
Rrd1 forms a complex with the TOR pathway members Tap42 and Sit4 [23, 60, 
77]. Overexpression of Tap42 suppresses the rapamycin resistance seen in rrd1Δ 
mutant strains [77]. Moreover, both Sit4 and Rrd1 work in the same pathway to 
mediate resistance to oxidative stress induced by 4-nitroquinoline 1-oxide (4NQO) 
and UVA [23]. 
As mentioned previously, rapamycin also induces a reorganisation in the 
transcription profile of genes [56]. Our lab showed that rrd1∆ mutant cells fail to 
downregulate expression of genes encoding ribosomal proteins such as RPS26A, 
RPL30 and RPL9 when treated with rapamycin. Preliminary data also revealed that 
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RNA pol II was not degraded as efficiently as in a WT strain following rapamycin 
treatment [78]. So far, the exact mechanism by which Rrd1 deletion leads to 
rapamycin resistance remains unknown, and investigating this phenomenon is a main 
goal of this thesis. 
 
1.2 RRD1/PTPA OVERVIEW 
 
RRD1 homologs exist in a variety of species such as Xenopus laevis [79], 
Drosophila melanogaster, and Schizosaccharomyces pombe [80].  It is highly 
conserved from yeast to human, showing 40% sequence identity with its human 
homolog PTPA (phosphatase two A phosphatase activator). An alignment is shown 
in Figure 1.1. 
S. cerevisiae also contains an RRD1 homolog called RRD2 showing 25% 
sequence identity. rrd2Δ mutant strains are also resistant to rapamycin and caffeine, 
but the phenotypes are weaker than rrd1Δ [24].  Deletion of both genes is lethal [24, 
25], suggesting functional redundance and revealing their critical importance for the 
cell. Expression of the mammalian counterpart PTPA can rescue lethality in the 
rrd1Δ rrd2Δ double mutant [24, 81]. We chose to focus on Rrd1 because the rrd2∆ 
rapamycin phenotype is less severe, rrd2∆ cells are not sensitive to oxidative stress, 
and a mammalian homolog for RRD2 has not yet been identified.    
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1.2.1 PTPA 
 
PTPA is encoded by a single gene on chromosome 9q34 in human 
(chromosome 2 in mouse) and consists of 10 exons and 9 introns [84]. The 
transcription factor yin yang 1 (YY1) is involved in the regulation of transcription of 
the PTPA gene [85]. PTPA also possesses multiple splicing sites resulting in seven 
distinctive products leading to the expression of 4 protein isoforms. However, only 2 
of these proteins are detectable in vivo [86]. 
 
1.2.2 Rrd1/PTPA structure 
 
Crystal structures of yeast Rrd1 and Rrd2 and human PTPA were solved using 
truncated peptides where non-structured regions were removed. Interestingly, the 
overall structures of all three proteins were very similar and were organized into an 
α-helical compact structure [87]. Comparison with known structures revealed no 
obvious similarity with any other previously analyzed proteins [88].  
Mammalian truncated PTPA protein contains 17 α helices and 4 short β 
strands. The structure is organized in 3 main domains: the core, the lid and the linker. 
The core is linked to the lid, located at the C-terminus, by the linker forming a large 
cleft. The structure also revealed a deep pocket of conserved amino acid residues 
between the core domain and the linker possibly representing a protein interaction 
domain [88]. It was previously reported that the conserved region 200GVWGLD205 is 
essential for the peptidyl prolyl isomerase activity (discussed in detail below) as well 
as activation of PP2A [80, 89].  
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1.2.3 PP2A 
 
As indicated by its name, PTPA was first described as an activator of protein 
phophatase 2A (PP2A) in rabbit skeletal muscle and Xenopus laevis oocytes [79]. 
The weak phosphatase activity of PP2A could be stimulated by PTPA in an ATP and 
Mg2+-dependent manner in vitro [90].  Mutational analysis has also shown that 
specific amino acids (V209D, E270A,V281D, G290D and M294D) are important for 
both the interaction between PP2A and PTPA and the ATPase activity of the complex 
[88]. The mechanism by which this occurs is still poorly understood [79, 90].  PP2A 
complexes are conserved serine/threonine phosphatases ubiquitously expressed in the 
cell and are important for the regulation of numerous signalling pathways [91]. 
Deregulation of PP2A is associated with cancer and Alzheimer’s disease [92-95]. The 
PP2A heterodimeric complex (Figure 1.2) is formed of a core dimer (PP2AD) 
containing a structural or scaffolding A subunit (PP2AA) and a catalytic C subunit 
(PP2AC), and each subunit can be found in 2 distinct isoforms (α or β). The core 
dimer can also associate with a regulatory B subunit (PP2AB) to form the 
heterotrimeric holoenzyme. There are 4 structurally different families of PP2AB : B 
(PR55), B’ (PR61), B’’ (PR48, PR72 or PR130, G5PR) and B’’’ (PR93 or PR110) 
and each family consists of 2 to 5 different isoforms [96].  
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1.2.3.1 Post-translational modifications 
 
Methylation of the PP2A holoenzyme is an essential mechanism of regulation 
[103-106]. Methylation of the carboxy-terminal Leu309 of the catalytic subunit 
(PP2AC) is important for recognition by some of the regulatory subunits (PP2AB) 
such as the regulatory subunit Bα [107, 108]. There is also evidence that inhibition of 
the methylation site in yeast leads to decreased formation of the holoenzyme [100]. 
Methylation is mediated by a conserved protein, a PP2A-specific leucine carboxyl 
methyltransferase (LCMT-1), and demethylation is catalysed by a PP2A-specific 
methylesterase (PME-1) [103, 109, 110]. Levels of this methyltransferase vary during 
the cell cycle, suggesting a role in cell-cycle regulation [91, 111]. The methylation 
status is critical for the differentiation of neuroblastoma cells and could possibly play 
an important role in Alzheimer disease [112, 113]. 
The catalytic subunit C of PP2A is also targeted for phosphorylation on 
Tyrosine 307 by tyrosine kinases such as pp60v- src, pp56lck, epidermal growth factor 
(EGF) and insulin receptors. Phosphorylation results in inactivation of the enzyme 
[114] and it has been associated with Alzheimer disease [115]. Phosphorylation of a 
regulatory B’ subunit (B56α) by the serine/threonine kinase PKR [116] seems to be 
important for apoptosis. In short, phosphorylation of B56α on Serine 28 activates the 
phosphatase activity required for dephosphorylation of Bcl2 and inhibition of 
apoptosis [117, 118]. 
 
 
 
17 
 
1.2.4 Rrd1/PTPA and PP2A 
 
In yeast, Rrd1 was found to interact with the PP2A-like phosphatases Pph3 
and Ppg1 [77]. It was also shown that Rrd1 and Pph3 act synergistically to induce 
rapamycin resistance in yeast [78]. The interaction with Pph3 was confirmed using 
affinity purification coupled with mass spectrometry analysis in mammalian cells 
[119].   
Deletion of PTPA homologs in yeast results in accumulation of PP2A and 
PME-1 complex and decreased methylation of the catalytic subunit (PP2AC) [120]. 
Also, inactive PP2A can be re-activated by PTPA in a Mg2+/ATP dependent manner 
in vitro [79], suggesting that PTPA inhibits the methyltransferase activity of PME-1 
[110]. It remains unknown how PTPA performs this activation, but an attractive 
possibility is that it acts as a cis/trans peptidyl prolyl isomerase on Proline 190 close 
to the active site of the catalytic C subunit of PP2A and this function will be 
discussed later [87, 89].  
Finally, a recent study suggested that depletion of PTPA with RNAi results in 
cell transformation caused by a defect in PP2A catalytic subunit C methylation. This 
defect altered the assembly of the catalytic subunit C with the scaffolding subunit A 
and suggests a novel role for PTPA as a tumor suppressor [121].   
 
1.2.5 PTPA and apoptosis 
 
To gain more insight into a possible function of PTPA, our laboratory 
previously monitored the biological response following transient overexpression of 
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PTPA labelled with the green fluorescent protein (GFP). The results showed cell 
death of the PTPA-overexpressing cells via p53-independent apoptosis in a time-
dependant manner. This apoptosis was independent of the mitogen-activated protein 
kinase (MAPK). Surprisingly, inhibition of PP2A with okadaic acid did not prevent 
the PTPA overexpressing cells from dying through apoptosis. The exact mechanism 
leading to apoptosis remains unknown, but nonetheless these data reveal that a 
specific level of PTPA is required for normal homeostasis of the cells [122].  
 
1.2.6 Rrd1/PTPA as a peptidyl prolyl isomerase (PPIase) 
 
A key breakthrough was the discovery that PTPA and its yeast homolog, 
Rrd1, possesses peptidyl prolyl cis/trans isomerase (PPIase) activity. PPIases are 
enzymes that convert proline residues between their two distinct isoforms, cis or 
trans (Figure 1.3). PPIases are highly conserved from yeast to human [123]. These 
ubiquitous enzymes can be divided into four structurally different families: 
cyclophilins (Cyps), FK-506 binding proteins (FKBPs), parvulins and the Ser/Thr 
phosphatase 2A (PP2A) activator PTPA. The catalytic domain of PTPA is an α-helix 
fold whereas the other PPIases are characterized by a central β-sheet [87, 124, 125].  
 Typically, the peptide bond linking amino acid residues in a protein adopts the 
trans isoform since this is the less energetic conformation as compared to the cis 
conformation. Interestingly, proline residues are the only amino acids in which both 
conformations are relatively energetically equivalent [126].  The possibility of having 
two distinct structures (cis and trans) can act as a molecular switch, similar to other 
post-translational modifications, enabling proteins to perform different functions 
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Another PPIase, Pin1, is a member of the parvulin family and has been found 
to play roles in a variety of cellular processes.  Pin1 is the only enzyme that can 
isomerise a specific motif formed of phosphorylated Ser/Thr-Pro [131]. Pin1 cis/trans 
isomerisation is involved in the control of cell growth regulation, genotoxic stress, 
and the immune response. Deregulation of Pin1 has been linked to Alzheimer’s 
disease, cancer and aging [132].  Interestingly, it has been shown that Pin1 binds to a 
pSer-Pro motif on the C-terminal domain (CTD) of the large subunit of RNA pol II 
and regulates the phosphorylation status of this domain through inhibition of the 
phosphatase FCP1 and stimulation of the kinase cdc2/cyclin B [133-135]. 
The PPIase activity of PTPA was discovered when PTPA was shown to 
isomerize synthetic PP2A catalytic subunit peptides in vitro [87, 89]. This led to a 
model in which isomerisation by PTPA could activate the phosphatase activity of 
PP2A. It is likely that PTPA and its yeast homolog Rrd1 isomerize other substrates, 
and identification of such substrates could explain its role in 4-NQO sensitivity and 
rapamycin resistance. Our lab previously showed that transcription of a subset of 
genes is deregulated in rrd1∆ cells [78].  This, along with the knowledge that Pin1 
isomerizes the CTD of RNA pol II, led us to investigate whether the CTD is also an 
Rrd1 substrate. We found that isomerisation of the CTD by Rrd1 does indeed play a 
major role in transcription regulation, and these data will be presented in Chapter 2. 
To provide the necessary background, a review of the transcription mechanism in 
eukaryotic cells is presented in the next section. 
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1.3 TRANSCRIPTION 
1.3.1 Overview 
 
Transcription is the mechanism by which RNA is synthesized from the DNA 
template. During this process, RNA polymerase reads from one strand of the double-
stranded DNA, called the template strand, whereas the other strand is termed the 
coding strand. The template strand is read in a 3’ to 5’ direction and the RNA is 
synthesized from 5’ to 3’, comparable to DNA replication. The resulting RNA is 
single-stranded and its sequence is identical to the coding strand except that uracil is 
substituted for thymine. Transcription can be divided into three major steps: 
initiation, elongation and termination. Since it leads to gene expression and is one of 
the most frequent events in a cell, it is highly regulated.   
In eukaryotic cells, there are three different RNA polymerases, which each 
transcribe a specific type of RNA. Each RNA polymerase is composed of 4 to 14 
polypeptides and requires the aid of distinct additional factors to perform its function. 
Ribosomal RNAs (rRNA) are synthesized by RNA pol I in the nucleus and are part of 
the 18S, 5.8S and 28S ribosomal subunits. These subunits are required for the 
assembly of the full ribosome, which is involved in the translation of messenger RNA 
(mRNA). Transcription of the rRNA represents around 60% of the transcription in a 
cell. Transfer RNA (tRNA) and the 5S subunit of rRNA are transcribed by RNA pol 
III and account for about 10% of the total transcription [136]. tRNAs are involved in 
transferring each amino acid to the polypeptide chain at the ribosome during 
translation, and 5S rRNA is another constituent of the ribosomal complex. Finally, 
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RNA pol II transcribes the mRNA in the nucleus.  Most mRNAs code for genes and 
are translated into proteins. RNA pol II also transcribes non-coding small RNAs such 
as small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and micro RNA 
(miRNA) [137]. Small non-coding RNAs are involved directly in many different 
cellular pathways, although the specific function of the majority of them remains 
unknown [138].  My thesis will focus on the regulation of RNA pol II. 
 
1.3.2 Transcription initiation 
 
 Initiation of transcription occurs at the core promoter, which is usually located 
upstream of the gene and contains specific sequences that recruit initiation factors. 
The TATA box, which is involved in about 30% of gene transcription, is found 
around 25 bases upstream of the transcription start site and possesses the consensus 
sequence TATAWAAR [139]. The TATA box is often associated with an initiator 
element (Inr) and both can act synergistically to activate transcription of abundantly 
expressed genes [140]. Another element called the downstream promoter element 
(DPE) activates transcription coupled to the Inr in TATA-less promoters [141]. All 
these markers are important to correctly direct the pre-initiation complex [142] to the 
site of transcription initiation. There are also cis-acting DNA sequence such as 
enhancers, silencers and insulators [143] and trans-acting elements such as the RNA 
pol II pre-initiation complex [142], transcription factors and chromatin remodeling 
proteins [144].  Transcription is highly regulated and these different elements can 
either activate or repress transcription. 
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 Various transcription factors join RNA pol II at gene promoters in an 
organized order. General transcription factors (GTFs) that are necessary for initiation 
include TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH. The formation of the PIC 
occurs by stepwise recruitment of the different GTFs to the promoter region and is 
initiated by TFIID binding to the core promoter. TFIID is a multi-subunit complex 
containing 14 different factors including TBP (TATA-binding protein) [145]. TBP is 
known to bind to this AT-rich region and unwind the DNA, forming a single-stranded 
“bubble” for the transcription machinery. TFIIB and TFIIA are then recruited and 
stabilize TFIID at the promoter region, followed by the recruitment of the RNA pol II 
complex already bound to TFIIF. At this point, transcription can only initiate when 
TFIIE and TFIIH join the complex. The ATP-dependant helicase activity of TFIIH 
melts the promoter, forming an “open” initiation complex and leading to the release 
of RNA pol II.  This is called promoter clearance and represents the beginning of 
transcription elongation [146]. 
 
1.3.3 Transcription elongation 
 
 Elongation is a highly regulated and critical step that is mandatory for the 
correct organization and integrity of the genome. This step begins when promoter 
escape is complete, when the new RNA associates stably with the transcription 
complex. TFIIB is important to stabilize this association as well as to allow 
elongation initiation [147, 148]. In yeast, DRB sensitivity-inducing factor (DSIF), 
consisting of Spt4, Spt5, and negative elongation factor (NELF) facilitates RNA Pol 
II pausing in the promoter-proximal region, and TFIIS also associates with the paused 
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polymerase [149]. This pause is necessary for capping enzymes to bind to the C-
terminal domain (CTD) (discussed in depth below) of Rpb1 phosphorylated on serine 
5 and Spt5 and to allow nascent RNA capping [150, 151]. Positive transcription-
elongation factor-b (P-TEFb) is involved in the phosphorylation of DSIF, NELF and 
serine 2 on the CTD leading to productive elongation [152]. TFIIF, eleven-nineteen 
lysine-rich in leukemia (ELL) and Elongin are the main factors that stimulate RNA 
pol II elongation and inhibit pausing [153]. TFIIF seems to be important for RNA pol 
II release from a stalled state [154]. Elongin is not active until the RNA transcript is 
8-9 nucleotides long and until TFIIF leaves the complex [155]. Finally, the last 
component of transcription elongation is topoisomerase I, which allows unwinding of 
the DNA throughout the process [156]. 
 Transcribing RNA pol II adopts three different states: a pretranslocation state 
where the nucleotide added to the RNA chain is still in the addition site, a 
posttranslocation state where the addition site becomes free and a backtracked state 
where RNA pol II performs a retrograde motion [157, 158]. RNA pol II backtracking 
of one residue is favorable whereas longer backtracking leads to a possible 
irreversible arrest [158] and this is detailed in a later section.   
Nucleosomes protect the DNA by keeping it in a tightly closed form, and this 
process must be reversed to let RNA pol II access the gene to be transcribed. Several 
factors involved in remodeling the chromatin have been identified and will be 
discussed briefly here. The first category includes ATP-dependent chromatin 
remodelling complexes that use ATP hydrolysis to modify the chromatin structure 
[159, 160]. In yeast, the Swi/Snf (Switch/Sucrose nonfermentable) complex moves 
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nucleosomes around and can repress or activate transcription depending on the 
situation [161, 162].  Histones chaperones, such as FACT and Spt6, regulate 
intracellular histone dynamics, histone storage and replication-associated chromatin 
assembly [163, 164].  
Acetylation of histones H3 and H4 is important during transcription 
elongation, and histone acetyltransferases (HATs) and deacetylases (HDACs) have 
been found in the coding region of multiple genes [165] although they are more 
commonly associated with the promoter and 5’ region [166]. It has also been 
documented that histone methylation, mostly on H3, is important for progression of 
transcription [167]. One example is Set2, which interacts with active genes through 
its affinity for RNA pol II phosphorylated on both serine 2 and 5 of the CTD [168-
170]. Finally, ubiquitylation of either histone H2B [171] or phosphorylation of 
histone H3 [172] are possible modification required for transcription elongation 
regulation.      
 
1.3.4 Transcription termination 
 
There are two proposed models for the termination of transcription: the 
torpedo model and the anti-terminator model. In the first model, cleavage of the 
polyadenylated site creates a new 5’-end, and exonuclease or helicase activity leads to 
the dissociation of RNA pol II [173]. The second model states that the appearance of 
the polyadenylation sequence on the RNA strand triggers a reorganisation in the 
binding factors, leading to a decrease in RNA pol II elongation [174]. Pausing of 
RNA pol II is also important for termination and occurs at the 3’-end of the gene, 10-
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30 nucleotides downstream from the hexanucleotide AAUAAA.  This specific 
sequence is recognized by the CPSF (cleavage and polyadenylation specific factor) 
group of proteins [175-178]. RNA pol II CTD regulation is also involved in 3’-end 
processing, but this will be discussed in a later section. 
Recent research supports a combination of both models. As mentioned 
previously, the torpedo model involves the activity of the yeast 5’-3’ exonuclease 
Rat1 (Xrn2 in mammals) in order to recruit the 3’-end processing factors, but this 
nuclease does not seem to be essential for cleavage at the poly(A) site [179, 180]. 
Xrn2 interacts with p54nrb and PSF (protein-associated splicing factor), which are 
involved in transcription, splicing and polyadenylation [181, 182]. Xrn2 action on the 
cleavage of the RNA product precedes the release of RNA pol II, as predicted by the 
second model [183].  
 
1.3.5 RNA polymerase II structure 
 
The RNA pol II holoenzyme is composed of 12 conserved subunits (termed 
Rpb1-12) resulting in a large complex of about 550 kDa [184]. All subunits are 
necessary for yeast cells to grow normally [185]. Three of the subunits are unique to 
RNA pol II: Rpb4, Rpb7 and Rpb9, whereas the rest are common to all RNA 
polymerases. The two major subunits Rpb1 and Rpb2 form the catalytic center and 
are homologous to subunits of the bacterial RNA polymerase [185]. Mutational 
analysis revealed that Rpb1 and Rpb2 are both required throughout the entire 
transcription process, from initiation to termination [186]. The largest subunit Rpb1 
contains a unique C-terminal domain (CTD) containing a heptapeptide repeated 26-
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Rpb1 can be found in two main forms during transcription: IIa, the 
hypophosphorylated form and IIo, the hyperphosphorylated form. The IIa form is 
preferentially found at the pre-initiation site whereas the IIo form is found later in the 
elongation process where each repeat is phosphorylated at least once [190]. 
Chromatin immunoprecipitation (ChIP) analysis revealed that Ser5 phosphorylation 
by the cyclin-dependant kinase (Cdk)7 (Kin28 in yeast), was higher at the 5’ region 
of a gene [191]. This phosphorylation is required to release the mediator complex 
from pol II, allowing recruitment of capping enzymes [192, 193].  
Once the transcription machinery leaves the initiation site, Ser2 
phosphorylation by Cdk9 (Ctk1 in yeast) is initiated and is important for binding of 
the 3’-RNA processing machinery.  This phosphorylation is most abundant at the 3’ 
end of the transcribed gene [194, 195]. Phosphatases such as SCP1 (Ssu72 in yeast) 
and Fcp1 dephosphorylate Ser5 and Ser2, respectively, and are required for the 
recycling of RNA pol II following transcription of a gene. Once RNA pol II reaches 
the polyadenylation signal, most of the Ser5 phosphorylation is gone and only Ser2 
remains. In this state, pol II interacts with the polyadenylation cleavage factor (Pcf)1. 
Interaction of the CTD with the 3’ processing factors is important for transcription 
termination.  More recently, several studies have shown that Ser7 play a role in 
transcription of snRNA genes [196] as well as some protein coding genes, and that 
this phosphorylation site seems to be important for termination [197].  
Throughout transcription, histone modifications are related to the 
phosphorylation status of the RNA pol II CTD. For example, the histone methyl-
transferases Set1 and Set2 are recruited by phosphorylated Ser5 and Ser2/Ser5, 
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respectively [198]. Taken together, the phosphorylation status of the CTD of RNA 
pol II is a useful tool to monitor each step in the transcription of a gene and a better 
knowledge of this mechanism represents the challenge of future investigation. 
Determining the precise phosphorylation status of each heptapeptide will be an 
important future goal for the transcription field.   
Each repeat of the RNA pol II CTD contains 2 possible prolines that could be 
isomerised. The mammalian Pin1 (Ess1 in yeast) PPIase isomerizes prolines preceded 
by phospho-serine or phosphor-threonine residues and inhibits Fcp1 phosphatase 
activity leading to inhibition of transcription [199]. It has been shown that Ess1 and 
Pin1 preferentially recognize both the Ser2 and Ser5 phosphorylated form of RNA 
pol II in vitro [200].  
Finally, reversible addition of a monosaccharide N-acetylglucosamine (O-
GlcNAc) has been found on serine and threonine residues, but it is still unknown how 
glycosylation regulates transcription [201]. Interestingly, both glycosylation and 
phosphorylation cannot be found simultaneously on the CTD [202]. 
 
1.3.6 RNA pol II arrest 
 
Transcription elongation can be interrupted at any point and various 
consequences can result from this arrest. As mentioned above, programmed 
transcriptional pausing is important for factors to join the complex, but unscheduled 
pausing can become problematic and lead to transcriptional arrest. DNA compaction 
into chromatin, DNA-binding proteins and DNA lesions can all represent possible 
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obstacles to transcription elongation. The interaction between RNA pol II and the 
DNA is highly stable and a blockage in transcription leading to an arrest can be 
lethal. Consequently, cells have developed a plethora of mechanisms to counteract 
these events.    
TFIIS is a general elongation factor (GEF) known to be important for releasing 
RNA pol II from transcriptional arrest. This arrest is recognized by the loss of contact 
between the 3’-end of the elongating RNA transcript and the RNA pol II active site 
following retrograde motion of RNA pol II. At this point, TFIIS re-established this 
link by endonucleolytically cleaving the RNA, known as cleavage-resynthesis [157]. 
Elongation factors are recruited and released dynamically throughout the elongation 
process and the association of RNA pol II with them is usually difficult to detect 
because of their transient nature. In the case of TFIIS, treatment with 6-azauracil 
(6AU), which decreases GTP and UTP intracellular levels and leads to an inhibition 
of elongation [203], can allow detection of TFIIS associated with RNA pol II by 
ChIP analysis [204].  
 
1.3.6.1 Transcription-coupled nucleotide excision repair (TC-NER) 
 
Transcription-coupled nucleotide excision repair (TC-NER) is an efficient 
mechanism to recognize transcription-blocking lesions on DNA and ultimately repair 
them. TC-NER is able to efficiently remove the two main photolesions induced by 
UV-C: cyclobutane pyrimidine dimers (CPD) and 6-4 photoproducts (6-4PP) [205]. 
The interaction between the elongating RNA pol II and the Cockayne’s syndrome B 
(CSB) protein (Rad26 in yeast) becomes more stable when the complex is blocked at 
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a lesion [206]. CSB allows the interaction of CSA with DNA which in turn recruits 
XPA-binding protein 2 (XAB2), the high-mobility-group nucleosomal binding 
protein (HMGN1) and TFIIS [207]. Other factors, such as SWI/SNF histone acetyl 
transferase and p300/CBP, modify the chromatin around the lesion to allow access to 
the repair machinery [208]. Defects in TC-NER result in Cockayne syndrome 
characterised by growth failure, impaired development of the nervous system, 
photosensitivity and premature aging [209]. It was shown that when the TC-NER 
complex is unable to repair the damage, Def1 recruits the ubiquitylation machinery 
and RNA pol II is degraded to allow repair of the lesion by global genomic repair 
(GGR), a separate branch of NER that is independent of transcription [210].   
 
1.3.6.2 RNA pol II ubiquitylation 
 
When RNA pol II becomes irreversibly stalled during transcription, as occurs in 
Cockayne syndrome patients, its removal from chromatin is the only option. The 
main mechanism for displacement of RNA pol II is ubiquitylation, leading to 
proteasomal degradation of the protein. Ubiquitin is a highly conserved (96% identity 
between yeast and human) protein of 76 amino acids found in all eukaryotes. 
Ubiquitylation is a protein post-translational modification process where ubiquitin is 
covalently linked to a lysine residue of the targeted protein. Ubiquitin is first 
activated by an E1 ubiquitin-activating enzyme using ATP, and is then transferred to 
an E2 ubiquitin-conjugating enzyme.  The E2 enzyme transiently carries the activated 
ubiquitin to an E3 ubiquitin ligase. The E3 transfers the ubiquitin from the E2 to the 
lysine of a specific substrate. The addition of multiple ubiquitins onto a substrate, 
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called polyubiquitylation, directs this substrate for degradation by the proteasome 
[142, 211]. 
Rpb1 can be ubiquitylated on only two lysines: K330 and K695 [212]. In yeast, 
the only known E1 is Uba1 and the E2 can be either Ubc5 or Ubc4 [213]. Rsp5 
(NEDD4 in mammals) is the E3 required for monoubiquitylation of Rpb1, whereas 
Elc1 is required for polyubiquitylation in response to DNA damage [214, 215]. The 
Rpb1 CTD is required for ubiquitylation, but it is unknown how the protein is 
recognized [213]. Finally, it has been shown that ubiquitylation of RNA pol II is also 
present without DNA damage, indicating that Rpb1 degradation occurs during 
normal, unperturbed transcription. The 19S regulatory particle of the proteasome is 
required for active transcription, supporting this idea [216].  
 
1.3.6.3 RNA pol II sumoylation 
 
It has been shown that RNA pol II elongation arrest following DNA damage 
leads to ubiquitylation-dependant degradation of the protein in order for TC-NER to 
take place [217]. RNA pol II degradation is still effective in CS cells, however, in 
which the ubiquitylation pathway is altered, indicating that RNA pol II can be 
degraded by a separate ubiquitin-independent mechanism [218]. Recent findings have 
shown that sumoylation of Rpb1 following UV radiation is necessary for this 
degradation [219]. Thus, sumoylation may be involved in Rpb1 degradation in some 
circumstances.  In yeast, the small ubiquitin-like modifier (SUMO) protein works in a 
three step enzymatic reaction similar to ubiquitin. 
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Based on the literature, we hypothesized that Rrd1 plays a role in regulating 
RNA pol II transcription through its peptidyl prolyl cis/trans isomerase activity and 
that this mechanism is conserved in mammals. The first objective is to determine 
whether Rrd1 localizes on the chromatin and interacts with RNA pol II. The second 
objective is to investigate the role of Rrd1 in the CTD isomerisation in response to 
rapamycin both in vivo and in vitro. Finally, the last objective is to understand the 
mechanism of RNA pol II degradation following rapamycin treatment. A better 
understanding of its role in transcription could explain the 4-NQO sensitivity as well 
as the rapamycin resistance of cells lacking Rrd1. The following two chapters 
(Chapter 2 and 3) of my thesis focus on papers published on a role for Rrd1 as a 
regulator of RNA pol II. The main finding of this work is that Rrd1 is associated with 
the chromatin and interacts with RNA polymerase II. In vitro and in vivo analysis 
with circular dichroism revealed that Rrd1 mediates structural changes of the C-
terminal domain of the large subunit of RNA pol II, Rpb1, in response to rapamycin 
and 4-NQO. Consistently, we demonstrated that Rrd1 is required to alter RNA pol II 
occupancy on rapamycin responsive genes. We also showed that upon rapamycin 
exposure Rrd1 mediates the degradation of RNA polymerase II and that this 
mechanism is ubiquitin-independent.  
We also hypothesised that Rrd1 function is conserved in mammalian cells. We 
first investigated PTPA function by performing its knockdown in mammalian cells 
using RNA interference (RNAi). The second objective of this work is to identify 
proteins interacting with PTPA. Finally, the last objective is to analyse the effects of 
PTPA knockout in mice. Chapter 4 presents results where PTPA knockdown did not 
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affect sensitivity to rapamycin, 4-NQO or H2O2. We also tried to find protein 
interaction partners for PTPA using tandem affinity purification, but no stable 
partners for PTPA were found. Finally, we attempted to study PTPA in a mouse 
model. We first determined that PTPA was expressed in a tissue-specific manner and 
was most abundant in the bone marrow, thymus and brain. We pursued creation of a 
knockout mouse and successfully generated chimeras, but the mutated allele was not 
transmitted to the germline. 
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2.2 ABSTRACT 
Background 
In Saccharomyces cerevisiae, the immunosuppressant rapamycin engenders a 
profound modification in the transcriptional profile leading to growth arrest. Mutants 
devoid of Rrd1, a protein possessing in vitro peptidyl prolyl cis/trans isomerase 
activity, display striking resistance to the drug, although how Rrd1 activity is linked 
to the biological responses has not been elucidated. 
Results 
We now provide evidence that Rrd1 is associated with the chromatin and it interacts 
with RNA polymerase II. Circular dichroism revealed that Rrd1 mediates structural 
changes onto the C-terminal domain (CTD) of the large subunit of RNA polymerase 
II (Rpb1) in response to rapamycin, although this appears to be independent of the 
overall phosphorylation status of the CTD. In vitro experiments, showed that 
recombinant Rrd1 directly isomerizes purified GST-CTD and that it releases RNA 
polymerase II from the chromatin. Consistent with this, we demonstrated that Rrd1 is 
required to alter RNA polymerase II occupancy on rapamycin responsive genes. 
Conclusion 
We propose as a mechanism, that upon rapamycin exposure Rrd1 isomerizes Rpb1 to 
promote its dissociation from the chromatin in order to modulate transcription. 
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2.3 BACKGROUND 
Rapamycin is an immunosuppressant that was recently approved for treating 
kidney carcinomas [1]. It is known to inhibit the Tor1 (Target of Rapamycin) kinase 
signalling pathway leading to growth inhibition [2]. In S. cerevisiae, several factors 
have been identified through genome-wide screens that when deleted cause resistance 
to rapamycin [3]. One of these proteins is Rrd1 (Rapamycin Resistance Deletion 1) 
that was first reported to play a role in protecting cells against oxidative DNA 
damage caused by the carcinogen 4-nitroquinoline-1-oxide (4-NQO) and by UVA 
[4]. Mutants deficient in Rrd1 are also unable to undergo rapamycin-induced growth 
arrest and therefore exhibit marked resistance to the drug [5]. Rrd1 is conserved in 
eukaryotes and shares 35% identity with the human phosphotyrosyl phosphatase 
activator, hPTPA, which was initially isolated as a protein that stimulated the weak 
phosphotyrosyl phosphatase activity of the type 2A Ser/Thr phosphatase PP2A [6, 7]. 
We and others reported that Rrd1 can physically interact with the Ser/Thr 
phosphatase Sit4, a PP2A like phosphatase [8-10]. In S. cerevisiae, rapamycin binds 
to the peptidyl-prolyl cis/trans isomerase Fpr1 and this drug-protein complex 
inactivates the Tor1 kinase causing a profound modification in the transcriptional 
profile, and culminating in G1 growth arrest [11-13]. Inhibition of Tor1 leads to the 
activation of Sit4, by virtue of its dissociation from the inhibitor complex Tap42-Sit4, 
which in turn dephosphorylates several targets including the nutrient-responsive 
transcriptional activator Gln3 that translocates to the nucleus to activate GLN1 and 
MEP2 expression [13-15]. However, these Sit4-dependent processes do not require 
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the function of Rrd1, suggesting that the latter protein might execute a function 
downstream in the Tor1 signalling pathway [12, 16-18]. 
Recent data indicate that Rrd1 exerts an effect at the transcriptional level [12, 
16-18]. Genes known to be upregulated (e.g., the diauxic shift genes CPA2 and 
PYC1) and down-regulated (e.g., the ribosomal protein genes including RPS26A, 
RPL30, and RPL9) following rapamycin exposure showed an altered transcription 
pattern in rrd1Δ mutants [12, 16-18]. To date, the exact function executed by Rrd1 
causing alteration in transcription has not been investigated. Rrd1 and its mammalian 
counterpart PTPA have been shown to possess an in vitro peptidyl prolyl cis/trans 
isomerase (PPIase) activity on model substrates [19]. PPIases are ubiquitous proteins 
that catalytically facilitate the cis/trans isomerization of peptide bonds N-terminal to 
proline residues within polypeptide chains [20, 21]. Both Rrd1 and PTPA can 
independently change the structure of short peptides including the synthetic substrate 
(186LQEPHEGPMCDL198) representing a conserved sequence amongst PP2A 
phosphatases [19]. As such, it has been suggested that Rrd1/PTPA could activate 
PP2As via this PPIase activity [19]. So far, neither the in vivo target nor the 
biological function of the PPIase activity of Rrd1 has been elucidated, although this is 
not the case for other PPIases. For example, the PPIases Ess1 and Pin1 from S. 
cerevisiae and mammalian cells, respectively, possess the ability to associate with the 
C-terminal domain (CTD) of Rpb1 [22, 23]. In yeast, the CTD consists of 26 repeats 
of the YS2PTS5PS7 heptad sequence and Ess1 has been shown to stimulate the 
dephosphorylation of Ser-5 to efficiently terminate transcription of a subset of genes 
[24]. 
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In this study, we show that Rrd1 is associated with RNA pol II and isomerizes 
the CTD of Rpb1 in vivo and in vitro. Our data suggest a model whereby this 
isomerization leads to the dissociation of RNA pol II from the chromatin resulting in 
transcriptional changes. This study provides insight into a possible new mechanism 
by which RNA pol II could rapidly respond to transcriptional changes. 
  
41 
 
2.4 METHODS 
2.4.1 Strains, media and plasmids 
 
The strains used in this study were the parents BY4741 (Mat a, his3-1, leu2-0, 
met15-0, ura3-0), YDL401 (MATa his3Δ200 leu2Δ1 trp1 ura3-52 gal2 galΔ108), and 
the isogenic mutants rrd1Δ and gln3Δ. Strains were endogenously and independently 
tag at the following loci APN1, RAD52, RRD1, SWE1 and YAP8 as previously 
described [25]. Strains bearing Rpb1-TAP was provided by Tom Begley (Albany, 
USA). Strains were grown in either rich (YPD) or selective (SD) media. Construction 
of pGFP-SIT4, pGFP-RAD52, pGFP-RRD1, GST-APN1 was previously described 
[8]. pGST-CTD was constructed by amplifying the murine CTD from plasmid 
pGCTD [26] and subcloned into pTW340 (provided by Tom Wilson, Michigan, 
USA). Construction of the plasmid pGAL-HIS-RRD1 and purification of HIS-Rrd1 
fusion protein were done as previously reported for pHIS-BLH1 [27]. 
 
2.4.2 Spot test analysis 
 
The assay was done as previously described, except that plates contained 
rapamycin [28]. 
 
2.4.3 Extraction of chromatin-associated proteins 
 
Extraction of proteins bound to chromatin was done as previously described, 
except for the high salt extraction [29]. 
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2.4.4 Co-Immunoprecipitation experiments 
 
Co-immunoprecipitation was done as previously described [8], except using 
8WG16 antibody (Covance) covalently coupled to AminoLink matrix (Pierce) and 
total extracts [30] prepared from cells expressing either MYC- or GFP-tagged form of 
the indicated proteins or from the untagged parent or rrd1Δ mutant cells. The matrix 
with bound proteins was washed four times with a buffer containing 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, and 0.1% NP40. The input (5%) used in the co-
immunoprecipitation experiment as well as half the volume of the matrix were 
assessed by Western blot using either anti-MYC, -GFP (Clontech), or -ubiquitin 
(Rockland). The remaining half of the matrix was analyzed separately by Western 
blot probed with 8WG16 antibody. 
 
2.4.5 GST and GST-CTD purification 
 
Strains bearing either pGST (this laboratory) or pGST-CTD plasmid were 
subcultured in 500 ml selective media to an OD600 of ~1.0, then treated with the 
appropriate drug for the indicated time. Cells were centrifuged, washed once with 
sterile water, and resuspended in 1.5 ml of yeast extraction buffer and extracts were 
prepared as above. The extracts were centrifuged at 3000 rpm in an Eppendorf 
centrifuge at 4°C for 3 min. Lysates were diluted 3-4 folds in PBS and Triton X-100 
was added to a final concentration of 0.2%. One and half ml of glutathione sepharose 
4B matrix (Pharmacia) was equilibrated with 50 ml of PBS in 50 ml Falcon tube then 
the lysate (~80 mg) was added and allowed to bind for one hour at room temperature 
on a rotating platform. The matrix was washed 3 times with PBS then transferred to 
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10 ml disposable column (BioRad). Excess of PBS was allowed to flow through, then 
GST-CTD was eluted with 10 fractions each of 150 μl of 50 mM Tris-HCl pH 9.0, 20 
mM reduced glutathione (Sigma). Peak fractions were pooled to a total volume of 
750 μl and the buffer was exchanged to 500 μl phosphate buffer using centricon 
(Millipore). Purity of the samples was verified by SDS-PAGE followed by silver 
staining. 
 
2.4.6 Purification of Rpb1-TAP 
 
Proteins were extracted from untreated or rapamycin-treated (200 ng/ml for 1 
h) cells as above and 2 mg were added to 40 μl of pre-equilibrated calmodulin affinity 
beads (Stratagene, USA). Purifications and washes were performed as described for 
the batch purification protocol provided by the manufacturer (Stratagene, USA). 
Eluates (50 μl) were collected, boiled and loaded onto SDS-PAGE for Western 
analysis. After probing with H5 or H14 antibody (Covance) membranes were stripped 
and re-probed with anti-PAP antibody (Sigma, USA). 
 
2.4.7 Western blot analysis of GST, GST-CTD and Rpb1-TAP 
 
BY4741 parent or rrd1Δ mutant cells expressing the GST-CTD or carrying 
the endogenous Rpb1-TAP tag were subcultured in the appropriate media and treated 
with rapamycin (200 ng/ml for 30 min). Whole cell extracts or where indicated 
affinity purified proteins (GST, GST-CTD or Rpb1-TAP using manufacturer's 
protocol (Stratagene, USA)) were analyzed by Western blot with anti-GST (Sigma), 
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H5 (anti-Ser2 phosphorylated) and H14 (anti-Ser5 phosphorylated) antibodies 
(Covance) or anti-PAP (Sigma). 
 
2.4.8 Interaction between Rrd1-MYC and GST-CTD 
 
Total protein extracts derived from parent cells (100 ml) expressing GST-
CTD or GST-Apn1, untreated or treated with rapamycin (200 ng/ml for 2 h) were 
allowed to bind to 1 ml GST affinity matrix slurry as described for the purification, 
except samples were not eluted from the columns. A second protein extract (1 mg) 
derived from a strain expressing Rrd1-MYC or Yap8-MYC was applied and allowed 
to bind for 1 h at room temperature on a rotating platform. The columns were then 
washed with 20 bed volumes of PBS and an aliquot of the beads (30 μl) was loaded 
onto an 8% SDS-PAGE and processed for Western blot. The presence of GST-CTD 
on both columns was detected using polyclonal anti-GST (Sigma) and the bound 
Rrd1-MYC was revealed using anti-MYC monoclonal antibody (SantaCruz). 
 
2.4.9 Circular dichroism spectroscopy 
 
Continuous far-UV circular dichroism spectra (197-250 nm) of the GST and 
the GST-CTD fusion protein (2.0 μg and 4.32 μg, respectively, in 100 μl of 10 mM 
phosphate buffer pH 7.0, 50 mM NaCl) were collected using a Jasco-810 
spectropolarimeter. The measurements were carried out at room temperature using a 
1 mm path-length cuvette (Hellma) and a 1 nm bandwidth. Three spectra were 
collected for each sample and averaged. The spectral contribution of the buffer was 
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corrected for by subtraction. Relative ellipticity was converted to mean residue molar 
ellipticity [Θ] according to Fasman [31]. 
 
2.4.10 Limited chymotrypsin digestion assay 
 
The purified GST-CTD (~100 ng) derived from parent cells untreated or 
treated with rapamycin (200 ng/ml for 2 h) was subjected to digestion with 5 ng 
chymotrypsin [32] in the presence of 1 mM CaCl2, and incubated at 37°C for the 
indicated time. Digestion was stopped by the addition of SDS-PAGE loading buffer 
and boiling of the samples. Processing of the GST-CTD was analyzed using 8% SDS-
PAGE followed by staining with silver. 
 
2.4.11 In vitro isomerase assay 
 
Purified HIS-Rrd1 (from E. coli using Talon affinity column according to the 
manufacturer (GE) protocol) was added to the purified GST-CTD in sodium 
phosphate buffer (10 mM NaPO4 pH 7.0, 50 mM NaCl) without or with 1 mM 
MgCl2, and 1 mM ATP in a final volume of 200 μl. The proteins were incubated for 1 
h at 30°C the GST-CTD was recovered by GST-affinity purification and then 
subjected to CD analysis. 
 
2.4.12 In Vitro Rpb1 release assay 
 
Exponentially growing culture (200 ml) of the BY4741 rrd1Δ Apn1-MYC 
strain was prepared and lysed as above for the extraction of chromatin associated 
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proteins. Supernatant was discarded and the pellet was washed once in 1 ml of 
isomerization buffer (10 mM NaPO4 pH 7.0, 50 mM NaCl, 1 mM MgCl2, and 1 mM 
ATP). Supernatant was discarded again and pellet was resuspended in 600 μl of 
isomerization buffer and equally divided in three tubes. Increasing amounts of 
purified HIS-Rrd1 were added and samples were rocked for 1 h at 30°C. Samples 
were then spun down and supernatant was kept for subsequent western blot analysis. 
The remaining pellet was resuspended in benzonase buffer (50 mM Tris pH 8.0, 1 
mM MgCl2) and 1 μl of benzonase (Novagen) was added and tubes were incubated 
for 30 min at 37°C. Supernatant (SOL) and chromatin [11] fractions were loaded onto 
SDS-PAGE gels for Western blot analysis with 4H8 (Cell Signaling) and anti-MYC 
antibodies. 
 
2.4.13 ChIP assay 
 
The ChIP assay was done as previously described [33]. Primers are available 
upon request. ACT1 was used as an endogenous control and relative quantity was 
calculated using the ΔΔCT method (Applied Biosystems). IP's were normalized to the 
respective input. Untreated IP samples were given an arbitrary unit 1 and increase or 
decrease folds were calculated. At least three independent experiments were done for 
each gene and Student T test was used to calculate the p-value. 
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2.5 RESULTS 
 
2.5.1 Rrd1 is associated with the chromatin and interacts with Rpb1 
 
We previously demonstrated that Rrd1 is required to modulate the expression 
of a subset of rapamycin-regulated genes independently of Sit4 [18]. To corroborate 
our earlier findings that Rrd1 acts separately from the Sit4-Gln3 signaling pathway, 
we deleted the RRD1 gene in the gln3Δ background (known also to be resistant to 
rapamycin) and examined the resulting gln3Δ rrd1Δ double mutant for the level of 
resistance to the drug [34]. This genetic analysis revealed that the gln3Δ rrd1Δ double 
mutant was significantly more resistant to rapamycin than either of the single mutants 
(Figure S2.1), suggesting that Rrd1 performs a distinct role to regulate response to the 
drug. 
To investigate this potentially novel role of Rrd1, we first checked whether 
Rrd1 binds to chromatin in light of its involvement in gene regulation [18]. 
Chromatin fractions were derived from strains expressing MYC-tagged Rrd1, as well 
as the control proteins Swe1, Rad52 and Apn1 from the endogenous loci and 
subjected to Western blot analysis probed with anti-MYC antibody. As shown in 
Figure 1.1A, a significant amount of Rrd1-MYC was found in the chromatin fraction 
(lane 3), suggesting that Rrd1 is associated with the chromatin and consistent with an 
earlier study showing that Rrd1 is also present in the nucleus [8]. In contrast, the 
control protein Swe1-MYC was only found in the soluble fraction (lane 2), while 
Rad52-MYC and Apn1-MYC, two DNA repair proteins known to bind chromatin, 
were present in the chromatin fraction (lane 3) [35, 36]. 
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Figure 2.1: Rrd1 is associated with the chromatin and interacts with Rpb1.  
A) Rrd1 is bound to chromatin. Whole cell extract (WCE), soluble (SOL) and 
chromatin [11] fractions were derived (see Methods) from the parent cells expressing 
either Rrd1-MYC, Swe1-MYC, Rad52-MYC or Apn1-MYC and the distribution of 
the MYC-tagged proteins was examined by Western blots. The data is representative 
of two independent analyses. B) Rpb1 pull-down of Rrd1. The 8WG16 antibodies 
were used to immunoprecipitate extracts from untreated (-) and rapamycin-treated 
(+) (200 ng/ml for 30 min) cells expressing either Rrd1-MYC or Swe1-MYC. The 
presence of Rrd1 in the immunoprecipitates was determined by Western blotting. C) 
Specificity of Rpb1 pull-down of GFP tagged proteins. The 8WG16 antibodies were 
used to immunoprecipitate extracts from cells expressing either of the following GFP 
tagged proteins: Imp2, Rrd1, Rad52 or Sit4. The presence of the GFP-tagged proteins 
in the immunoprecipitates was detected by Western blotting using GFP antibody. 
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amount of Rrd1 co-immunoprecipitated by anti-Rpb1 when cells were treated with 
rapamycin (200 ng/ml for 30 min) (Figure 2.1B). 
Anti-Rpb1 also co-immunoprecipitated Rrd1 from parent cells carrying a 
plasmid expressing GFP-tagged Rrd1 (Figure 2.1C). In addition, the Sit4 phosphatase 
known to physically interact with Rrd1 [8] co-immunoprecipitated with Rpb1 from 
parent cells expressing this protein as GFP fusion (Figure 2.1C). Two additional GFP 
fusion proteins, GFP-Imp2 and GFP-Rad52, which do not interact with Rrd1, were 
not co-immunoprecipitated with anti-Rpb1 antibody, although a minute amount of 
GFP-Rad52 non-specifically interacted with the beads used for immunoprecipitation 
(Figure 2.1C, and data not shown). Thus, Rpb1 associates with proteins known to 
bind Rrd1, suggesting that Rrd1 could exist in a complex with Rpb1. We note that the 
reverse co-immunoprecipitation with Rrd1-MYC did not pull down Rpb1 under the 
same reaction conditions, raising the possibility that the size of the RNA pol II 
complex might impede the pull down although we cannot exclude other alternatives 
such as a weak or indirect interaction via another protein. 
 
2.5.2 Rrd1 associates with the CTD of Rpb1 and alters its structure in response 
to rapamycin 
 
Since the C-terminal domain (CTD) of Rpb1 is a repeated sequence 
(YSPTSPS) rich in proline residues, and has previously been shown to bind the 
isomerases Ess1 and Pin1 [22, 23, 37], we reasoned that Rrd1 could function to 
isomerize the CTD. As such, we assessed whether the CTD is a substrate for the 
PPIase activity of Rrd1 in vivo. The CTD was expressed as a GST fusion protein 
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from a previously described plasmid (see Methods) and has been shown to undergo 
post-translational modifications including Ser-5 and Ser-2 phosphorylation, 
isomerization and ubiquitylation [24, 26, 32, 38]. Introduction of this plasmid into the 
parent and rrd1Δ strains directed the expression of the GST-CTD fusion protein with 
the expected size (95-kDa) as determined by Western blot analysis probed with anti-
GST antibodies (Figure 2.2A, see also Figure S2.2). The GST-CTD contained both 
phosphorylated Ser-5 and Ser-2 as detected by anti-H14 and anti-H5 antibodies, 
which specifically recognize Ser-5 and Ser-2 phosphorylation, respectively (Figure 
2.2A), consistent with previous studies that the GST-CTD can be functionally 
modified in vivo [26, 32, 38, 39]. From these analyses, we observed no differences in 
the (i) size, (ii) level of expression, and (iii) phosphorylation of the GST-CTD 
whether it was derived from the parent or the rrd1Δ mutant or from cells that were 
pretreated with rapamycin (Figure 2.2A, Figure S2.2). 
 
Figure 2.2 : Analysis of the GST-CTD and its interaction with Rrd1. 
A) Comparison of the expression and phosphorylation status of the GST-CTD 
between parent and rrd1Δ mutant cells following rapamycin exposure. The indicated 
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control for equal protein loading the membranes were stripped and reprobed with the 
anti-PAP antibody. Results shown are representative of three independent 
experiments.  
 
 
We next prepared GST-CTD affinity beads from parent cells and determined 
whether these could pull down Rrd1. Total extract derived from the parent strain 
expressing Rrd1-MYC (Figure 2.2B, lane 2) was incubated with the GST-CTD 
affinity beads. The beads were recovered, washed and an aliquot examined for 
retention of Rrd1-MYC by Western blot analysis. As shown in Figure 2.2C and 2.2D, 
Rrd1-MYC was pulled down by the GST-CTD affinity beads. In contrast, the GST-
CTD affinity beads did not pull down the transcriptional activator Yap8, also tagged 
with MYC (Figure 2.2B, 2.2C and 2.2D). As expected, the empty beads did not pull 
down Rrd1-MYC from the total extract nor did the control beads carrying GST-Apn1 
(Figure 2.2C and 2.2D). These data support the notion that Rrd1 associates with the 
CTD of Rpb1, consistent with the above observation that Rpb1 co-
immunoprecipitated Rrd1. 
We next investigated whether Rrd1 could induce conformational changes in 
the GST-CTD fusion protein by using circular dichroism (CD) spectroscopy, a 
method that is very sensitive to changes in the secondary structure of proteins [31]. 
We first purified the GST-CTD from the parent and the rrd1Δ mutant, as well as GST 
from the parent to be used as the control. Silver stain analysis of the purified GST-
CTD revealed that there was no difference in the size of this protein, whether it was 
derived from the parent or the rrd1Δ mutant (Figure 2.3A, lane 3 vs. 5) or when the 
cells were treated with rapamycin (lane 3 vs. 4 or 5 vs. 6). As observed for total 
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extract, the purified GST-CTD also contained both phosphorylated forms, Ser-2 and 
Ser-5, but showed no alteration in response to rapamycin (Additional file 1 Figure 
S2A). To ensure that the observed phosphorylation status of the GST-CTD is similar 
to Rpb1 CTD phosphorylation, we purified Rpb1 from the TAP tagged strains and 
monitored this protein for its phosphorylation. Like the GST-CTD, Rpb1-TAP 
showed no differences in either Ser-5 or Ser-2 phosphorylation following rapamycin 
treatment (Additional file 1 Figure S2B). However, this approach may not distinguish 
between subtle phosphorylation differences that may occur amongst the heptad 
repeats [40]. Since the GST-CTD is similarly phosphorylated as the endogenous 
Rpb1, we used it as a tool for further analysis. 
 CD spectra obtained for the purified GST-CTD derived from either the 
untreated parent or rrd1Δ mutant were indistinguishable, and displayed a minimum at 
202 nm (Figure 2.3B). In contrast, GST-CTD derived from the parent cells treated 
with rapamycin exhibited a spectrum with a minimum at 208 nm and shoulder at 
~225 nm (Figure 2.3B), suggesting that the GST-CTD underwent a detectable change 
in its secondary structure. Remarkably, rapamycin treatment of the rrd1Δ mutant 
failed to induce this conformational change onto the GST-CTD (Figure 2.3B). 
Introduction of a single copy plasmid expressing functional Rrd1 in the rrd1Δ mutant 
restored the change in the spectral pattern of the GST-CTD (Figure 2.3C) [4]. 
Additionally, purified GST alone derived from untreated or rapamycin treated parent 
cells did not exhibit any structural differences, suggesting that it is the CTD portion 
of the fusion protein that is undergoing the rapamycin-induced changes (Figure 
2.3D). We further confirmed the structural change of the GST-CTD as observed by 
CD using limited proteolysis with chymotrypsin, which can distinguish proteins with 
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different secondary structures and exclusively cleaves peptides in the trans-proline 
conformation [41]. As shown in Figure 3E, the GST-CTD purified from the 
rapamycin-treated parent cells was more resistant to limited chymotrypsin digestion, 
as opposed to the GST-CTD derived from the untreated cells, suggesting that indeed 
the GST-CTD went through a structural reorganization in response to rapamycin. On 
the basis of these findings, it would appear that the CTD of Rpb1 changes its 
structure in vivo following exposure to rapamycin, and that Rrd1 is essential for this 
alteration. 
 
 
Figure 2.3 :  rrd1Δ mutants are unable to induce conformational changes to the 
GST-CTD in response to rapamycin. 
A) Silver stained gel of purified GST and GST-CTD. The indicated strains carrying 
either the GST (lanes 1 and 2) or GST-CTD expressing plasmid (lanes 3-6) were 
untreated (-) or treated (+) with rapamycin (RAP) (200 ng/ml for 30 min). B) Far-UV 
circular dichroism (CD) spectral analysis of purified GST-CTD. The purified GST-
CTD (0.45 μM) was derived from the parent strain (triangle) or rrd1Δ mutant (circle) 
that were untreated (opened symbol) or treated (closed symbol) with rapamycin. C) 
Far-UV CD spectral analysis of purified GST-CTD. The purified GST-CTD (0.45 
μM) was derived from the rrd1Δ mutant carrying the empty vector (circle) or the 
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pRRD1 plasmid (triangle) that were untreated (opened symbol) or treated (closed 
symbol) with rapamycin. D) CD analysis of purified GST (0.76 μM) derived from 
untreated (opened symbol) and rapamycin treated (closed symbol) parent cells as 
above. Results shown are the averages of two independent experiments. E) Limited 
proteolysis of purified GST-CTD derived from parent cells untreated or treated with 
rapamycin. The purified GST-CTD was subjected to partial chymotrypsin digestion 
and analyzed by silver staining. Results shown are representative of two independent 
experiments. 
 
 
 
2.5.3 Rrd1 alters the GST-CTD structure in response to 4-NQO, but not MMS 
 
We next checked if isomerization of the CTD is specific for rapamycin. Since 
the rrd1Δ mutant was previously shown to be sensitive to the DNA damaging agent 
4-NQO [4], which induces oxidative stress as well as creating bulky lesions onto the 
DNA [42], we examined for isomerization of the GST- CTD in the parent and the 
mutant following treatment with this drug. We observed that the structure of the 
GST-CTD was altered in the parent, but not in the rrd1Δ mutant following 4-NQO 
treatment (Figure 2.4A). We also tested another DNA damaging agent, methyl 
methane sulfonate (MMS) (Figure 2.4B), to which the rrd1Δ mutant displays parental 
sensitivity [4]. MMS creates apurinic/apyrimidinic sites in the genome, and for this 
experiment it was used at a concentration that kills ~70% of the cells. Under this 
condition, the GST-CTD showed no structural alteration following the MMS 
treatment (Figure 2.4B). On the basis of these findings, it would appear that this 
phenomenon might occur for other stress conditions besides exposure to rapamycin. 
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Figure 2.4 :  4-NQO, but not MMS, induces structural changes onto the GST-
CTD. 
A and B) CD analysis of the purified GST-CTD derived from exponentially growing 
parent (triangle) and rrd1Δ mutant (circle) that were untreated (opened symbol) or 
treated (closed symbol) with either 4-NQO (2 μg/ml 30 min) panel A or MMS (1% 
for 60 min) panel B. 
 
2.5.4 Rrd1 directly alters the structure of the CTD in vitro 
 
We next examined whether purified Rrd1 can induce structural changes onto 
the CTD in vitro. To do this, we incubated equimolar amounts of recombinant HIS-
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Rrd1 purified from E. coli (Figure 2.5A) with affinity purified GST-CTD derived 
from the rrd1Δ mutant at 30°C for 30 min, and then recovered the GST-CTD for CD 
analysis. As shown in Figure 2.5B, purified HIS-Rrd1 significantly modified the CTD 
structure under the standard phosphate buffer reaction conditions. Since the Rrd1 
isomerase activity has been shown to be stimulated by ATP and Mg2+ [19], we 
examined the effect of these additions to the reaction mixture. Inclusion of ATP and 
Mg2+ in the buffer caused no structural alteration to the CTD in the absence of Rrd1 
(Figure 2.5B). However, addition of purified HIS-Rrd1 to the complete ATP/Mg2+ 
phosphate buffer introduced a more dramatic change to the CTD structure, as 
compared to the mixture lacking ATP/Mg2+ (Figure 2.5B). Moreover, the purified 
HIS-Rrd1 did not confer any structural changes onto another purified GST fusion 
protein, GST-Apn1 (data not shown). These findings suggest that Rrd1 can directly 
isomerize the CTD. 
 
 
Figure 2.5 :  Purified recombinant Rrd1 alters the structure of purified GST-
CTD in vitro.  
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A) Silver stained gel of purified recombinant HIS-Rrd1 from E. coli expression 
system (see Methods). Lanes 1-2 and 3-4 are elution samples from two independent 
purifications obtained directly from Talon affinity column; lane 5, molecular weight 
standard. B) Equimolar amounts (4.5 μM) of purified GST-CTD derived from the 
rrd1Δ mutant and the purified recombinant HIS-Rrd1 (triangle) were incubated at 
30°C in phosphate buffer in the absence (opened symbol) and presence (closed 
symbol) of Mg2+/ATP. The resulting GST-CTD was re-purified free of the 
recombinant HIS-Rrd1 and subjected to CD analysis as in Figure 2.3. The result is 
the average of two independent experiments. 
 
 
2.5.5 Comparison of RNA pol II occupancy at rapamycin-responsive genes 
 
Since Rrd1 associates with and isomerizes the CTD, and that rrd1Δ mutant 
did not affect the phosphorylation status of Rpb1, we asked whether it would alter 
RNA pol II occupancy on rapamycin responsive genes in vivo. To do this, we 
performed chromatin immunoprecipitation (ChIP) analysis of Rpb1 on two known 
RNA pol II-responsive genes, RPS26A and CPA2 [33]. Since both genes are known 
to be rapidly downregulated and upregulated, respectively, within 30 min, we treated 
cells for this time period with rapamycin [11, 18]. In parent cells, the Rpb1-ChIP 
signal from the RPS26A gene was reduced by nearly 8-fold upon rapamycin treatment 
(Figure 2.6A). In contrast, Rpb1 remained associated with RPS26A in the rrd1Δ 
mutant (Figure 2.6A). In the case of the upregulated gene CPA2, we observed an 
increase in Rpb1-ChIP signal in the parent upon rapamycin, whereas in the mutant 
there was only a modest increase in the signal (Figure 2.6B). The occupancy of RNA 
pol II on these genes is consistent with the mRNA expression levels [11, 18]. These 
data raise the possibility that Rrd1 might displace Rpb1 in order to optimize rapid 
transcriptional changes caused by rapamycin. 
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Figure 2.6 :  Comparison of RNA pol II occupancy at the indicated target genes 
in the parent and rrd1Δ mutant strain in response to rapamycin treatment.  
Cells were untreated or treated with 200 ng/ml rapamycin for 30 min and Rpb1 
localization was analyzed by ChIP assay (see Methods). Primer locations are 
indicated below the diagram. The respective input normalized IP amounts were 
quantified relative to the ACT1 gene using the ΔΔCT method. Results are shown as 
the average of three independent experiments. Error bars represent standard deviation 
and the P-values compare untreated vs. treated. 
 
 
 
 
2.5.6 Purified Rrd1 stimulates the release of chromatin-bound RNA pol II in 
vitro 
 
To explore the above possibility, we examined if purified Rrd1 would displace 
RNA pol II from the chromatin. Briefly, we isolated chromatin containing RNA pol 
II derived from the rrd1Δ mutant, the chromatin was washed and resuspended in the 
standard phosphate buffer containing ATP and Mg2+. To this reaction, increasing 
amounts of purified Rrd1 was added and following incubation the levels of 
chromatin-bound and soluble Rpb1 were monitored by Western blot. As shown in 
Figure 2.7 increasing concentration of Rrd1 caused a loss of chromatin-bound Rpb1, 
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while there was a correlating gain in the soluble fraction. In contrast, Rrd1 
concentration did not affect the level of the control protein Apn1-MYC. Collectively, 
our data indicate that Rrd1 possesses the ability to isomerize the CTD of Rpb1 
thereby promoting its displacement from the chromatin. 
 
 
 
Figure 2.7 :  Purified recombinant Rrd1 dissociates Rpb1 from the chromatin 
in vitro.  
Increasing amounts of purified HIS-Rrd1 were added to the chromatin fraction 
isolated from rrd1Δ mutant strain expressing Apn1-MYC and incubated at 30°C for 
1 h in phosphate buffer. Chromatin was recovered from the buffer and both fractions 
were analyzed by Western blotting probed with 4H8 (against Rpb1) and anti-MYC 
antibodies. Apn1-MYC was used as loading control. Result shown is representative 
of at least three experiments. 
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2.6 DISCUSSION 
 
In the present study, we show that Rrd1 is a chromatin bound protein, which 
associates with RNA pol II and presumably through the CTD of Rpb1. We believe 
that this association allows isomerization of the CTD in response to specific stress 
such as that caused by rapamycin and 4-NQO. In addition, we show that in vitro 
purified Rrd1 (i) can directly alter the structure of the CTD and (ii) dissociate Rpb1 
from the chromatin. On the basis of these observations, we propose the following 
model whereby in response to specific stress conditions the RNA pol II associated 
Rrd1 isomerizes the CTD of Rpb1 such that the polymerase is dissociated from the 
chromatin. Once the RNA pol II is released it would be recruited to stress-responsive 
genes. 
There is supporting evidence that elongating RNA pol II is in excess on 
ribosomal protein genes, surprisingly associated with a low transcriptional rate under 
glucose grown conditions [43]. However, once these cells are submitted to a 
metabolic change, e.g., a switch to galactose growth conditions, the level of RNA pol 
II decreased on these ribosomal genes and the transcriptional rate increased [43]. This 
shift also simultaneously caused an enrichment of RNA pol II onto mitochondrial 
genes [43]. This suggests a mechanism where excessive RNA pol II is removed from 
the ribosomal genes and recruited to mitochondrial genes to increase expression. 
Therefore, metabolic switches would stimulate re-localization of elongating RNA pol 
II from one regulon to the other. As it is known that rapamycin mimics starvation 
conditions and represses ribosomal biogenesis, we suspect a similar mechanism as the 
glucose-galactose shift is operational to rapidly change transcription. Besides Rrd1, 
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another well characterized peptidyl prolyl isomerase Pin1 can trigger the release of 
RNA pol II from transcribing genes in human cells [23]. Under normal conditions, 
Pin1 interacts with the phosphorylated CTD of RNA pol II and this association is 
retained along the length of transcribed genes [23]. However, when Pin1 is 
overexpressed it promotes hyperphosphorylation of the CTD during the transition 
from initiation to elongation, thereby causing RNA pol II to dissociate from active 
genes and leading to the inhibition of transcription [23, 44]. The dissociated RNA pol 
II accumulates in enlarged speckle-associated structures enriched for transcription 
and RNA processing factors [23, 45]. 
Because Rrd1 intersects with the biological functions of Pin1, it is possible 
that Rrd1 could modulate the phosphorylation status of the CTD. Recent studies 
showed that the yeast homologue of Pin1, Ess1, binds and catalyzes the cis/trans 
isomerization of the CTD such that Ser-5 phosphorylation can be dephosphorylated 
by the Ssu72 phosphatase [24]. Moreover, a variant of Ess1 (Cys120Arg) caused 
accumulation of Ser-5 phosphorylation, and not Ser-2 phosphorylation, both of which 
were monitored using the same set of antibodies (anti-H5, -H14 and -8WG16) as in 
this study [24]. We found no alteration in the global Ser-2 and Ser-5 phosphorylation 
status upon rapamycin treatment, as well as between the parent and the rrd1Δ mutant 
using the same set of antibodies (Figure 2.2A and Additional file 1 Figure S2). As 
such, it would seem that Rrd1 uses a novel mechanism independent of 
phosphorylation to isomerize the CTD, although we cannot exclude the possibility 
that there are unique Ser-2 and Ser-5 phosphorylation differences which can be 
masked by neighboring phosphorylations, for example, where one heptad is 
phosphorylated, but not the adjacent [40]. However, since RNA pol II exists in 
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different phosphorylation forms throughout the transcription cycle, it seems logical to 
have a mechanism that triggers RNA pol II release independent of its phosphorylation 
status. 
In yeast, the CTD consists of 26 repeats of the heptad sequence YSPTSPS. It 
exists largely in a disordered structure, but adopts a static conformation upon 
interaction with target proteins such as the mediator complex that regulates 
transcription initiation and enzymes that modify the 5' and 3'ends of mRNA[46, 47]. 
Binding of these proteins to the CTD is modulated by serine phosphorylation and 
proline isomerization [40]. Thus, a given heptad repeat could give rise to many 
different conformations with the various combinations of phosphorylated Ser-2, -5 
and -7, as well as the cis/trans isomerization of the two prolines, Pro-3 and Pro-6, to 
generate a broad range of binding sites to allow precise association with several 
factors [46-48]. At least three CTD interacting proteins (Pcf1, Pin1, and Ctg-1 from 
C. albicans) have been shown to bind exclusively the all-trans conformation, 
providing support for the hypothesis that proline isomerization of the CTD plays a 
critical regulatory role [48]. This strongly suggests that multiple conformations of the 
CTD exist in vivo. Consistent with this notion, we observed by CD analysis two 
conformations of the CTD that remained stable throughout its purification (Lisa 
Miller, Brookhaven National Laboratories, personal communications) from untreated 
and rapamycin-treated cells (Figure 2.3). These different conformations could be the 
result of proline isomerization, as prolines are known to be stable in either the cis or 
trans conformation when the protein is in a folded form [49]. Only peptidyl prolyl 
isomerases such as Pin1/Ess1 are known to trigger a switch between the cis and trans 
conformations of the CTD [50], and that in the absence of these enzymes the 
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conformational switch is slow [51]. Because Rrd1 possesses peptidyl prolyl 
isomerase activity and it associates with RNA pol II, it seems likely that this function 
is responsible for inducing structural changes to the CTD upon rapamycin exposure. 
In support of this, Rrd1 directly alters the CTD structure in vitro (Figure 2.5), and we 
therefore predict that Rrd1 might act in a similar manner onto the CTD in vivo. 
In addition to rapamycin, we also observed that the DNA damaging agent 4-
NQO, but not MMS, triggered alteration of the CTD structure (Figure 2.4). We 
examined the effect of 4-NQO, as we had previously shown that rrd1Δ mutants were 
sensitive to this agent and not to MMS [4]. The distinct difference between 4-NQO 
and MMS is that the former agent potently induces the production of reactive oxygen 
species such as superoxide anions [42]. Both starvation and oxidative stress are 
known to mediate similar transcriptional programs, also termed as the environmental 
stress response, for example, where ribosome biogenesis is turned off [51, 52]. This 
would explain why the rrd1Δ mutants are sensitive to 4-NQO, but resistant to 
rapamycin; (i) genes required for counteracting the 4-NQO-induced oxidative stress 
are not turned on efficiently and as a result the cells accumulate genotoxic lesions, 
and (ii) under rapamycin condition nutrients are still available and the failure to alter 
gene expression allows rrd1Δ mutants to grow. 
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2.7 CONCLUSION 
 
Taken together, our data suggest that Rrd1 participates in a novel mechanism 
that allows redistribution of RNA pol II for transcriptional regulation of genes 
involved in specific stress conditions. These results provide the first direct evidence 
that Rrd1 acts in vivo as an isomerase and establish a physiological function for this 
activity. 
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3.2 ABSTRACT 
In Saccharomyces cerevisiae, the immunosuppressor rapamycin engenders the 
degradation of excessive RNA polymerase II leading to growth arrest but the 
regulation of this process is not known yet. Here, we show that this mechanism is 
dependent on the peptidyl prolyl cis/trans isomerase Rrd1. Strikingly this degradation 
is independent of RNA polymerase II polyubiquitylation and does not require the 
elongation factor Elc1.  Our data reveal that there are at least two alternative 
pathways to degrade RNA polymerase II that depend on different type of stresses.  
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3.3 INTRODUCTION 
Rapamycin is an immunosuppressant that was recently approved for treating 
kidney carcinomas [1]. It is known to inhibit the Tor1 (Target of rapamycin) kinase 
signaling pathway leading to growth inhibition [2]. In Saccharomyces cerevisiae, 
rapamycin binds to the peptidyl-prolyl cis/trans isomerase Fpr1 and this drug–protein 
complex inactivates the Tor1 kinase causing a profound modification in the 
transcriptional profile, and culminating in G1 growth arrest [3-5]. We have reported 
that Rrd1 (rapamycin resistance deletion 1) is required for an efficient transcriptional 
response to rapamycin via the Tor1 signaling pathway [6, 7]. In fact, Tor1 mediated 
transcriptional changes are partially inhibited in rrd1Δ mutants [7]. Additional studies 
revealed that Rrd1 interacts with elongating RNA polymerase II (henceforth referred 
to as RNAPII) and that it regulates the rapamycin induced transcriptional response 
during the elongation of RNAPII [7]. Further, we demonstrated that Rrd1 isomerizes 
the C-terminal domain (CTD) of Rpb1 the major subunit of RNAPII and that it 
releases it from the chromatin as part of the regulatory process [8]. Interestingly, the 
response to rapamycin is kinetically associated with a diminished level of Rpb1, and 
which is blocked in the rrd1Δ mutants [6]. since RPB1 mRNA expression level was 
not significantly altered in response to rapamycin shown by three distinct genome 
wide expression analyses, and that RNAPII occupancy of the RPB1 gene was not 
changed as revealed by ChIP on chip analysis [3, 7, 9, 10], it thus appears that the 
decreased level of Rbp1 is associated with the degradation of the protein [6]. 
However, the exact function executed by Rrd1 that leads to RNAPII degradation has 
not been investigated yet. The degradation of RNAPII was initially observed in 
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response to DNA damage, such as UV radiation and by 4-nitroquinoline-1-oxide (4-
NQO), an oxidant causing bulky adducts onto the DNA [11-15]. During this process 
RNAPII is polyubiquitylated on two lysine residues (K330 and K695) and this event 
is crucial for its degradation [16, 17]. This is mediated through an ubiquitin-ligase 
complex containing the elongation factor Elc1 [14, 15]. To date this is the only 
pathway known to degrade elongating RNAPII in response to stress [16, 18]. 
In this study, we asked the question whether Rrd1 is involved in the 
rapamycin induced degradation of RNAPII. Indeed, Rrd1 is required for this process 
and we show that this is neither strain specific nor an antibody artifact. More 
importantly, Rrd1 is required at the level of the chromatin, executing its function 
through its catalytic peptidyl-prolyl isomerase domain for the release of RNAPII 
from the chromatin. Surprisingly, we find that this mechanism is ubiquitylation 
independent as it does not require the ubiquitylation sites of RNAPII or the ubiquitin 
ligase complex as in the case of DNA damage. We propose a model where the 
isomerization of the CTD of RNAPII by Rrd1 leads to the dissociation of RNAPII 
from the chromatin resulting in transcriptional changes and the degradation of the 
surplus polymerase. This study provides insight into an alternative mechanism of 
RNAPII degradation in response to transcriptional stress. 
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3.4 MATERIALS AND METHODS 
3.4.1 Strains, media, plasmids and antibodies 
 
The strains used in this study were the BY4741 (Mat a, his3-1, leu2-0, met15-
0, ura3-0), YDL401 (MATa his3Δ200leu2Δ1 trp1 ura3-52 gal2galΔ108), CY4029 
(W303 background, SSD1-v1, MATa, ade2-1, can1-100, his3-11, 15, leu2-3, 112, 
trp1-1, ura3-1), and SEY6210 [19] and the isogenic mutants rrd1Δ. Strains were 
endogenously and independently tag at the following loci APN1 and RAD52 as 
previously described [19]. The tor1-1 allele was derived from the W303 parental 
background and provided by Dr. Joseph Heitman (Duke University Medical Center, 
Durham, NC, USA). Rpb4-MYC and Rpb1-TAP were provided by Tom Begley, 
Albany, USA. Strains bearing the native Rpb1 and the mutants K330R and K695R 
were provided by Svejstrup, UK [20]. The strains were grown in either rich (YPD) or 
selective (SD) media. Antibodies used for Rpb1 were 8WG16 (Covance), 4H8 (Cell 
signaling) and anti-PAP (Sigma). Anti-MYC antibodies were purchased from Santa 
Cruz and anti-ubiquitylation antibodies from assay designs. 
 
3.4.2 Analysis of degradation of Rpb1 from whole cell extracts 
 
Overnight cultures of the indicated strains were subcultured for 3 h and treated 
with rapamycin, 4-NQO or MMS (Sigma–Aldrich) for different times. The total 
protein extracts were then prepared as previously described using a mini-bead-beater 
[21] and separated by SDS–PAGE and analyzed by Western blot. Protein amounts 
from the Western blots were quantified using Multi Gauge V3.0 program [22]. 
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3.4.3 Co-immunoprecipitation 
 
Co-immunoprecipitation was done as previously described [23], except using 
8WG16 antibody (Covance) covalently coupled to AminoLink matrix (Pierce) and 
total extracts [21] prepared from cells from the parent or rrd1Δ mutant cells. The 
matrix with bound proteins was washed four times with a buffer containing 50 mM 
Tris–HCl (pH 7.5), 150 mM NaCl, and 0.1% NP40. The input (5%) used in the co-
immunoprecipitation experiment as well as half the volume of the matrix were 
assessed by Western blot using anti-ubiquitin. The remaining half of the matrix was 
analyzed separately by Western blot probed with 8WG16 antibody. 
 
3.4.4 Spot test analysis 
 
Overnight cultures of the W303 strains bearing the native Rpb1 or the mutants 
K330R and K695R were diluted and spotted onto YPD solid agar plates without and 
with rapamycin. 
 
3.4.5 Extraction of chromatin-associated proteins 
 
Extraction of proteins bound to chromatin was done as previously described, 
except for the high salt extraction [24]. 
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3.4.6 In vitro chromatin assay 
 
Experiment was performed as described in Jouvet et al., besides that the 
plasmid expressing Rrd1 was mutated within the Rrd1 catalytic domain on residue 
D200G using the site directed mutagenesis kit (Stratagene) [8]. 
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3.5 RESULTS AND DISCUSSION 
3.5.1 Rrd1 is required for efficient RNAPII degradation in response to 
rapamycin 
 
To begin investigating the underlying mechanism of how Rpb1 levels are 
decreased in response to rapamycin, we decided to look at its protein level using 
multiple genetic backgrounds [6]. Total cell extracts derived from the wild-type strain 
BY4741 and the isogenic rrd1Δ mutant were treated with rapamycin and examined 
for levels of Rpb1 using the antibody 8WG16 which recognizes the C-terminal 
domain (CTD) of the protein. In wild-type cells, rapamycin triggered a substantial 
decrease in the level of Rpb1 in a time-dependent manner, while the decrease was 
less prominent in the rrd1Δ mutant (Fig. 3.1A). At least 60% of Rpb1 disappeared in 
the wild-type within 60 min of rapamycin treatment, while the level diminished 
significantly less (no more than 30%) in the rrd1Δ mutant under the same conditions 
(see quantification data shown below panel A). Similar results were obtained in three 
other genetic backgrounds (W303, SEY6210 and FY56) (Fig. 3.1 and data not 
shown). As such, Rpb1 levels decrease in a Rrd1-dependent process, but 
independently of the genetic background. 
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Figure 3.1 : rrd1Δ or tor1-1 mutants are unable to efficiently degrade RNAPII 
in response to rapamycin. 
(A–I) Exponentially growing wild-type yeast and the isogenic rrd1Δ mutant or the 
tor1-1 mutant allele, expressing either Apn1-MYC, Rad52-MYC, Rpb4-MYC or 
Rpb1-TAP from the endogenous locus, were treated with rapamycin (200 ng/ml for 
0–120 min). Total protein extracts were subjected to Western blot analysis using the 
indicated antibodies. RNAPII levels were calculated where the untreated is assigned 
an arbitrary unit of 1 and the treated calculated accordingly. The data is 
representative of at least three independent analyses. 
 
 
 
To exclude the possibility that the disappearance of Rpb1 triggered by 
rapamycin is due to a general increase in protein degradation, we monitored the level 
of several other proteins including the DNA repair proteins Apn1 and Rad52, as well 
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as Rpb4, a component of RNAPII. The wild-type and rrd1Δ mutants expressing 
MYC-tagged proteins from the endogenous loci were treated with rapamycin as 
above and the total cell extracts probed with anti-MYC antibody. No significant 
changes were observed in the levels of these proteins (Fig. 3.1B, D, E and F), 
suggesting that rapamycin does not invoke a general protein degradation response, 
and that Rpb1 might be the only subunit of RNAPII complex that is degraded as 
reported for 4-NQO [25]. To ensure that the observed degradation of Rpb1 was not a 
reflection of the 8WG16 antibody preferentially recognizing the unphosphorylated 
form of the CTD [26-28], we conducted similar experiments in the same strain using 
a different antibody (4H8) which recognizes both the phosphorylated and 
unphosphorylated forms of the CTD of Rpb1 [29]. The 4H8 antibody also revealed 
that rapamycin triggered a decrease in Rpb1 level in the wild-type, but only modestly 
in the rrd1Δ mutant (Fig. 3.1C). In contrast, the control protein Apn1-MYC was not 
degraded (Fig. 3.1D). Additionally, we conducted similar experiments in a strain 
where Rpb1 was tagged with the tandem affinity purification tag (TAP) at the 
endogenous locus. We then monitored for Rpb1 level by using an antibody (anti-
PAP) that recognizes the tag instead of the CTD of Rpb1. Anti-PAP also revealed 
that rapamycin triggered a decrease in Rpb1-TAP level in the wild-type, but only 
modestly in the rrd1Δ mutant (Fig. 3.1G). Thus, the various antibodies (8WG16, 4H8 
and PAP) are indeed monitoring loss of Rpb1, instead of changes in post-translational 
modifications such as phosphorylation of the CTD. 
The response to rapamycin is mediated through the TOR signaling pathway 
and thus we would expect less Rpb1 degradation if the TOR1 gene is mutated. As this 
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gene is essential, we used the conditional tor1-1 mutant allele, which is known to be 
resistant to rapamycin [30]. We monitored whether Rpb1 is degraded over time in the 
tor1-1 allele in response to rapamycin (Fig. 3.1H and I). Clearly, this tor1-1 mutant 
allele was not able to degrade Rpb1 in response to rapamycin indicating that this is 
mediated through the TOR signaling pathway. 
Since the loss of Rpb1 was monitored from total cell extracts, we next 
examined if this effect would be a reflection of the chromatin-bound Rpb1 in 
response to rapamycin. For this experiment, we used an established approach that 
separates soluble proteins from chromatin-bound [24]. In the untreated wild-type or 
rrd1Δ mutant, a significant amount of Rpb1 was found associated with the chromatin 
fraction (Fig. 3.2A, lane 3 and 9). Upon rapamycin treatment, nearly all of the Rpb1 
in the soluble and chromatin fraction was lost in the wild-type cells (Fig. 3.2A lane 6 
vs. 3); consistent with the notion that Rpb1 undergoes rapamycin-induced 
degradation. In contrast, the chromatin fraction derived from rapamycin-treated 
rrd1Δ mutant contained a substantial level of Rpb1 (Fig. 3.2A, lane 12 vs. 9), while 
the level in the soluble fraction was almost undetectable (Fig. 3.2A, lane 11). In these 
experiments, no major changes were observed for the control protein Apn1-MYC 
after rapamycin treatment (Fig. 3.2B). 
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Figure 3.2 : Rrd1 is required for the release of RNAPII from chromatin. 
(A and B) Wild-type and rrd1Δ mutant strains expressing Apn1-MYC were 
challenged with (+) and without (−) rapamycin (200 ng/ml for 120 min) and whole 
cell extract (WCE), soluble (SOL) and chromatin [3] fractions (see Section 3.4) were 
analyzed for RNAPII and Apn1-MYC by Western blots. The data is representative of 
three independent analyses. (C) Purified HIS–Rrd1 (native and mutant G200D at a 
concentration of 1.6 μM) were added to the chromatin fraction isolated from rrd1Δ 
mutant strain expressing Apn1-MYC and incubated at 30 °C for 1 h in phosphate 
buffer. Chromatin was recovered from the buffer and both fractions were analyzed 
by Western blotting probed with 4H8 (against Rpb1) and anti-MYC antibodies. 
Apn1-MYC was used as loading control. Result shown is representative of at least 
three experiments. 
 
 
 
Next we tested whether the catalytic activity of Rrd1 is required for the 
process of releasing RNAPII from the chromatin. Using an in vitro assay, we 
recently documented that purified Rrd1 is capable of releasing RNAPII from the 
chromatin [8]. Basically, the chromatin is isolated from whole cells and the amount 
of attached RNAPII is monitored by Western blot assay. Addition of purified Rrd1 
was shown to release RNAPII from the chromatin into the supernatant [8]. The 
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question remained whether Rrd1 acts through its catalytic peptidyl prolyl isomerase 
domain. To test this, we mutated a key residue in the catalytic center of the isomerase 
domain (D200G), known to abolish isomerase activity and tested whether this 
catalytic inactive mutant of Rrd1 is able to release RNAPII from the chromatin (Fig. 
3.2C) [31-33]. The result showed that the wild-type form of Rrd1 was capable of 
releasing RNAPII from the chromatin (lane 3) into the soluble form (lane 6), but not 
the mutant D200G (lane 2 vs. 5), suggesting that indeed isomerization is an essential 
step for the release of RNAPII. Taken together, the data suggest that chromatin-
bound RNAPII is degraded in a Rrd1-dependent manner in response to rapamycin. 
Our recent observation that Rrd1 acts as an elongation factor to regulate gene 
expression in response to rapamycin [7] raised the possibility that under starvation 
conditions, such as rapamycin treatment, the excessive RNAPII is removed from 
anabolic genes and moves to stress responsive and catabolic genes. Thus, when 
starvation persists the excessive RNAPII is degraded. Based on these findings, we 
believe that the transcriptional changes are associated and likely causal for the 
degradation of RNAPII [6, 7]. 
 
3.5.2 Rapamycin induces degradation of Rpb1 independent of ubiquitylation 
 
Several stress conditions are known to induce degradation of Rpb1 through 
the ubiquitin/proteasome pathway [11, 12, 34]. For example, DNA damaging agents 
such as 254 nm-UV and 4-NQO cause elongating RNAPII to stall, leading to 
ubiquitylation-dependent RNAPII degradation [11-15]. Since this is the only known 
pathway of RNAPII degradation in response to stress, we reasoned that ubiquitylation 
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would mediate the loss of RNAPII following rapamycin treatment and this process 
could be defective in the rrd1Δ mutant, thereby leading to stable RNAPII levels. To 
examine the ubiquitylated form of RNAPII in total extracts, we immunoprecipitated 
RNAPII with anti-RNAPII antibody from rapamycin treated cell extracts and probed 
with a monoclonal anti-ubiquitin antibody [25]. To avoid bias introduced by 
rapamycin-induced RNAPII degradation, we only treated cells up to 60 min since 
further treatment caused substantial degradation of RNAPII (Fig. 3.1). In addition, we 
used an excess of total protein extract (2 mg) in comparison to a limiting amount of 
beads (20 μl) conjugated to anti-8WG16 to perform the immunoprecipitation. This 
resulted in the immunoprecipitation of similar amounts of RNAPII which were then 
probed with anti-ubiquitin (Fig. 3.3A). As shown in Fig. 3.3B, a basal level of 
ubiquitylated RNAPII existed in both the wild-type and the rrd1Δ mutant (lane 5 vs. 
7), which is thought to represent RNAPII engaged in elongation [20]. Following 
rapamycin treatment for 60 min, the level of ubiquitylated RNAPII was unaltered in 
either strain (Fig. 3.3B, lane 6 vs. 8), suggesting that rapamycin does not appear to 
induce ubiquitylation of Rpb1. In control experiments, 254 nm-UV increased the 
level of ubiquitylated RNAPII to the same extent in both the wild-type and the rrd1Δ 
mutant, indicating that the ubiquitylation process of RNAPII is not impaired in the 
mutant (data not shown). 
To further investigate if ubiquitylation is associated with RNAPII in response 
to rapamycin, we examined the RNAPII mutants K330R and K695R, which cannot 
be ubiquitylated, for degradation [17]. Total cell extracts derived from the wild-type 
carrying either the native RNAPII or its mutants showed a similar extent of 
degradation of the protein in response to rapamycin, again suggesting that rapamycin-
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induced degradation of RNAPII is independent of ubiquitylation (Fig. 3.3C). In 
addition, we tested the RNAPII mutants for resistance to rapamycin (Fig. 3.3D). 
Rrd1Δ mutants are highly resistant to rapamycin and we would expect, if Rrd1 acts 
through ubiquitylation of RNAPII that the mutants K330R and K695R to be resistant. 
However, these mutants showed wild-type sensitivity to rapamycin and deleting the 
RRD1 gene in this strain background increased the resistance to rapamycin indicating 
that the ubiquitylation pathway is not associated with Rrd1 function (Fig. 3.3D). 
 
 
Figure 3.3 :  Ubiquitylation of RNAPII is not required for its response to 
rapamycin. 
(A) Total extracts (lanes 1–4) from either wild-type or rrd1Δ cells treated with (+) 
and without (−) rapamycin (200 ng/ml for 60 min) were immunoprecipitated with 
8WG16 antibodies (lanes 5–8). (B) The total extracts and immunopreciptates from 
panel A were probed with anti-ubiquitin antibodies. The data is representative of 
three independent analyses. (C) Western blot analysis of RNAPII degradation in 
RNAPII mutants from wild-type (WT) and rrd1Δ mutant cells (Δ) without (−) and 
with (+) 200 ng/ml rapamycin for 2 h. (D) Spot test analysis of the wild-type and the 
RNAPII mutants on YPD or YPD media containing 5 ng/ml of rapamycin (RAP). 
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(E) Exponentially growing Apn1-MYC tagged wild-type (WT) or elc1Δ mutant 
strain were untreated (−) or treated (+) with rapamycin (200 ng/ml, 120 min) and 
total protein extracts were probed with anti-RNAPII (8WG16) to monitor the level of 
Rpb1. The membranes were probed with anti-MYC antibody to monitor for equal 
protein loading. (F) Same as in (E) except that cells were untreated (−) or treated (+) 
with 4-NQO (3 μg/ml, 60 min). 
 
We finally decided to monitor for RNAPII degradation in an elc1Δ mutant 
strain since Elc1 is essential for the polyubiquitylation of RNAPII following DNA 
damage [14]. The different strains carrying Apn1-MYC endogenously tagged were 
treated with rapamycin (200 ng/ml, 120 min) (Fig. 3.3E) or 4-NQO (3 μg/ml, 60 min) 
(Fig. 3.3F) and whole cell protein extracts were monitored using 8WG16 antibody. 
Our results showed that RNAPII was degraded after rapamycin treatment in the elc1Δ 
mutant strain similar to the wild type strain (Fig. 3.3E). On the other hand, in the 
same elc1Δ mutant strain, RNAPII was not degraded in response to 4-NQO (Fig. 
3.3F, lane 4) demonstrating the Elc1 requirement for RNAPII degradation for this 
specific DNA damaging agent. Apn1-MYC expression was monitored as a loading 
control. Taken together our results exclude a role of the Elc1-ubiquitylation pathway 
in the degradation of RNAPII following rapamycin treatment. 
To summarize, (i) we confirmed that RNAPII is degraded in response to 
rapamycin in several strain backgrounds, (ii) that isomerization by Rrd1 is required 
for this process at the level of the chromatin and that (iii) this happens through an 
ubiquitylation independent pathway. The question still remains how RNAPII is 
degraded in response to rapamycin. One exciting possibility is that Rrd1 isomerizes 
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the CTD of Rpb1, already shown by our group, so that RNAPII becomes more 
susceptible for cleavage of its CTD resulting in its degradation [8]. 
It was previously demonstrated that in response to UVC radiation RNAPII is 
also degraded [25]. However, this degradation is dependent on ubiquitylation and not 
on the function of Rrd1 (data not shown), clearly indicating a different degradation 
pathway of RNAPII. UVC radiation induces specific DNA lesions and if these are not 
removed they can effectively block the movement of RNAPII during transcription. 
As a consequence, the stalled RNAPII is ubiquitylated and subsequently degraded 
[20, 25]. So far, there is no direct evidence that rapamycin can generate DNA lesions 
and, as such, we believe that this drug induces degradation of the excess RNAPII that 
arises as a result of the massive transcriptional reorganization. Despite the distinct 
modes of degradation of RNAPII triggered by the two different stresses, DNA 
damage and rapamycin, there seems to be some commonalities in the mechanisms. 
Both modes of degradation of RNAPII are mediated through elongation factors (Elc1 
and Rrd1) and in both cases transcription of RNAPII is affected. 
In conclusion, we propose that RNAPII is degraded by different mechanisms 
depending on the type of stress. In light of recent reports, we believe that rapamycin 
could cause a different marking of RNAPII such as acetylation and the resulting 
marked RNAPII is degraded via the autophagy pathway [35, 36]. 
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4.2 ABSTRACT 
 
PTPA, the mammalian homolog of Rrd1, has been shown to activate protein 
phosphatase 2A (PP2A). Our laboratory previously found that overexpression of 
PTPA leads to apoptosis independently of PP2A. The molecular function of 
Rrd1/PTPA is still largely unknown and our research in yeast reveals a novel role in 
transcription regulation and we believe it could be similar in mammals. 
 We showed that PTPA knockdown did not affect sensitivity to rapamycin, 4-
NQO or H2O2. We also attempted to find protein interaction partners for PTPA using 
tandem affinity purification, but no stable partners for PTPA were found. In addition, 
mass spectrometry showed no evidence for phosphorylation or ubiquitylation. 
Finally, we attempted to study PTPA in a mouse model. We first determined that 
PTPA was expressed in a tissue-specific manner and was most abundant in the bone 
marrow, thymus and brain. We pursued creation of a knockout mouse and 
successfully generated chimeras, but the mutated cells were not transmitted to the 
germline.  
My data and other data from our laboratory regarding the yeast work suggest a 
general role for Rrd1 in gene regulation. Whether PTPA has a similar function in 
mammalian cells remains unknown, and a different vision of what the protein does in 
mammalian cells will be required to adequately address this question in the future.   
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4.3 INTRODUCTION 
 
After characterizing the role of Rrd1 in RNA Pol II regulation in yeast [1, 2], 
we next sought to investigate the human homolog of Rrd1, PTPA, using cell culture 
and mouse models. The PTPA gene is found at the 9q34 region in human and 
translocations resulting in leukemia have been reported at this locus [3]. The PTPA 
gene is highly expressed in several tissues such as the brain, kidney, liver, spleen and 
testis [4]. It has also been shown that PTPA transcription is higher in lymphoblastoid 
cells in comparison with monocytic cells [3]. In mammalian cells, PTPA was first 
characterized as a protein that stimulates the weak phosphotyrosyl phosphatase 
activity of the type 2A Ser/Thr phosphatase PP2A [5] dependant on Mg2+ and ATP in 
vitro. PP2A family members are important Ser/Thr phosphatases that regulate a 
plethora of cellular pathways [6, 7] and their regulation still remains poorly 
understood.  
The crystal structure of PTPA does not show similarity to any known family 
of proteins. PTPA has 17 α helices and 4 short β strands and adopts a compact α-
helical structure [8] and this structure is conserved in yeast since comparison in the  
overall structures of Rrd1, Rrd2 and PTPA are essentially identical [11]. PTPA 
structure can be divided into three subdomains; lid, core and linker. The protein 
contains 323 amino acids and around 40 conserved residues among five species 
(Homo sapiens, Xenopus laevis, Drosophila melanogaster, Caenorhabditis elegans 
and Saccharomyces cerevisiae) are exposed on the surface of the PTPA protein 
between the core and the linker domains and could likely be an important binding site 
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for partners such as PP2A members. Analysis of 18 point mutation among the 
invariant amino acids described previously lead to differential interaction with PP2A 
suggesting a role for PTPA in the regulation of these phosphatases. For example, five 
mutations, V209D, E270A, V281D, G290D and M294D showed compromised 
binding to PP2A and indeed low or undetectable ATPase activity from the complex 
[8]. A recent study in which the PP2A interaction network was analysed identified 
multiple subunits of the chaperonin containing TCP-1 (CCT) as partners of PTPA, 
but the biological function of this interaction remains unknown [9]. Finally, studies 
previously performed by our lab showed that overexpression of PTPA in mammalian 
cells lead to apoptosis via a caspase 3-dependent pathway. This apoptosis was also 
independent of PP2A, MAP kinase, and p53 [10]. 
Like its yeast homolog Rrd1, PTPA is a peptidyl prolyl cis-trans isomerase 
(PPIase). PTPA has been shown to isomerize synthetic peptides derived from the 
catalytic subunit of PP2A [11]. The previous chapters of my thesis have shown that 
Rrd1 isomerizes the RNA pol II CTD in response to rapamycin, leading to Pol II 
degradation via a ubiquitylation independant pathway. Based on the findings in yeast 
and because PTPA is highly conserved, we hypothesized that PTPA performs a 
similar function in mammalian cells independently of its PP2A function. This chapter 
will describe our attempts to study PTPA in mammalian systems using a variety of 
approaches.  
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4.4 MATERIAL AND METHODS 
 
4.4.1 Cells, culture conditions and siRNA transfection 
 
HCT116 human colorectal carcinoma, HeLa cervical cancer cells, U2OS 
osteosarcoma cells, K562 human immortalised myelogenous leukemia cell line, and 
Phoenix virus-producing cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-
streptomycin. The small interfering RNA (siRNA) were purchased from Ambion 
(Austin, TX; catalog no.16704 and 4611) and transfection efficiency was measured 
using the Silencer FAM-Labeled Negative Control #1 siRNA (catalog no. 4620; 
Ambion). The small hairpin RNA (shRNA) were purchased from Sigma-Aldrich. 
Cells were transfected with either a nontargeting control or a PTPA RNA interference 
(RNAi) plasmid using Lipofectamine 2000 (Invitrogen). 
 
4.4.2 Western blotting  
 
Cells were transfected as above with either siRNA against PTPA or the 
nontargeting control siRNA and harvested by trypsinization at various times post-
transfection followed by centrifugation at 1000 rpm for 1 min. Cell pellets were 
resuspended in 100 μl of lysis buffer containing 150 mM NaCl, 1 mM EDTA, 10 mM 
Tris HCl, 1% w/w sodium deoxycholate, 1% v/w Nonidet P-40, 2 µg/ml aprotinine, 1 
µg/ml leupeptine, 1 mM sodium vanadate (Na3VO4) and 1 µM PMSF.  Samples were 
incubated on ice for 1hr, centrifuged at 14000 rpm for 30 min, and total protein in the 
supernatant was quantified by the Bradford assay.  Protein extracts were resolved on 
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10% denaturing polyacrylamide gels and transferred by electroblotting to a 
nitrocellulose membrane (Amersham Biosciences).  After blocking with 5% nonfat 
dry milk in Tris buffered saline (1 X TBS containing 50 mM Tris and 150 mM NaCl 
pH 7.5), the membrane was incubated with the indicated primary antibodies 
overnight at 4°C.  Primary monoclonal antibodies include anti-PTPA (Upstate) -p53 
(DO-1, Santa Cruz), -p21 (Ab-1,Calbiochem), -PCNA (PC10, Santa Cruz), -COX VI 
(Cell Signaling Technology), -HA (Santa Cruz) and -Tubulin (Santa Cruz). 
Immunoreactive proteins were localized with horseradish peroxidase–conjugated 
secondary antibodies (Amersham Biosciences) for 1h at room temperature and 
visualized using enhanced chemiluminescence (Perkin Elmer Las, Boston, CA). 
 
4.4.3 Colony formation assays.  
 
HCT116 cells (~1 X 106) were plated in 60 X 15 mm plates and incubated for 
24h. Cells were treated with siRNA. Cells were trypsinized (Gibco) and treated with 
the appropriate drug or taken at various times post-transfection, centrifuged (1000 
rpm for 1 min), diluted, and seeded in triplicate at a density of 500-1000 cells 
(Beckman cell counter) per 60 mm plate containing 5 ml of fresh media, and allowed 
to form colonies for 12 to 14 days.  The colonies were stained with methylene blue 
(0.5% methylene blue in 50% methanol). 
 
4.4.4 Chromatin assay 
 
Cells (5 x 106) were washed with PBS and resuspended in 150 µl of the lysis 
buffer (10 mM Hepes (pH 7.5), 10 mM KCl, 3 mM MgCl2, 0.35 M sucrose, 0.1% 
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NP40, 3 mM 2-mercaptoethanol, 0.4 mM PMSF, 1 µM pepstatin A, 1 µM leupeptin 
and 5 µg/ml aprotinin). The cells were incubated on ice for 5 min. Cytoplasmic 
proteins were removed from nuclei by centrifugation at 1300 g for 5 min. The nuclei 
pellet was resuspended in lysis buffer and nuclei were spun down by centrifugation. 
Isolated nuclei were resuspended in 200 µl of solution containing 3 mM EDTA, 0.2 
mM EGTA, 1 mM dithiothreitol, 100 mM NaCl and 0.8% NP40. The nuclei were 
incubated on ice for 60 min, and soluble nuclear proteins (soluble fraction) were 
separated from chromatin by centrifugation at 1700 g for 5 min. The chromatin pellet 
was washed twice with the same solution as the above and spun down at high speed 
(10 000 g for 1 min), and the chromatin was resuspended in SDS sample buffer and 
sheared by sonication (chromatin fraction). Both fractions were subjected to 
SDS/PAGE and immunoblot analysis [12]. 
 
4.4.5 Isolation of RNA and RT-PCR 
 
Total cellular RNA was isolated from HCT116 cells using TRIzol reagent 
(Invitrogen). A total of 5 μg of total RNA were reverse-transcribed in 20 μl of 
reaction mixture containing the RT buffer (Invitrogen), 10 mM dithiothreitol 
(Invitrogen), 1 mM each deoxynucleotide triphosphate (dNTP) (Amersham 
Biosciences), 40 units of RNaseOUT (Invitrogen), 0,6 μg of random primers 
(Invitrogen) and 20 units of Moloney murine leukemia virus reverse transcriptase 
(Invitrogen).  
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4.4.6 Mitochondrial fractionation 
 
Cells transfected with the PTPA siRNA or nontargeting control siRNA were 
fractionated using the mitochondria isolation kit for cultured cells (PIERCE). The 
different fractions were subjected to western blotting analysis. 
 
4.4.7 Cell cycle analysis 
 
At various time points, PTPA siRNA or negative control siRNA transfected 
cells were washed with PBS containing 50 mM EDTA, trypsinized, resuspended in 1 
ml of PBS/EDTA and fixed by addition of 3 ml of ice-cold 100% ethanol. Fixed cells 
were pelleted, washed with 4 ml of PBS/EDTA and stained with modified Krishan 
buffer [0.05 mg/ml propidium iodide (PI) (Sigma-Aldrich), 0.1% sodium citrate, 0.2 
mg/ml RNase A and 0.3% v/v NP40] and analyzed using a FACScan flow cytometer 
equipped with CellQuest software (Beckton Dickinson).  
 
4.4.8 Purification of PTPA-associated proteins and co-immunoprecipitation 
 
HeLa cell line stably expressing Flag-HA-PTPA (WT) was generated following 
retroviral transduction and 3 rounds of selection using magnetic beads as previously 
described [13]. HeLa (9 x 109) cells were used for the purification of PTPA-
associated proteins, essentially as previously described [13] using the whole cell 
extract. Mass spectrometry analysis was provided by the Taplin Mass Spectrometry 
Facility (Harvard Medical School, Boston, MA). Standard coimmunoprecipitations 
using appropriate antibodies were conducted as previously described [14]. 
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4.4.9 Plasmids 
 
Retroviral constructs that express N-terminal Flag-hemagglutinin (HA)-tagged 
wild-type (WT) or mutant forms of human PTPA were generated by subcloning the 
cDNA into the POZ-N plasmid provided by E. Affar [13]. The catalytically inactive 
PTPA construct, POZ-PTPA (G205D), POZ-PTPA (V209D) and POZ-PTPA 
(G290D) were generated by site-directed mutagenesis using the QuikChange 
Lightning Kit (Stratagene).  
 
4.4.10 Generation of knockout mice and genotyping 
 
 The mouse 129S2/SvPas embryonic stem cell (ESC) line D3H, carries a 
Ptpa allele disrupted by the insertion in the first intron of a gene trap vector 
(U3NeoSV1) kindly provided by the Sanger Institute Gene Trap Resource (SIGTR). 
The U3NeoSV1 promoter-trap provirus contains the ampicillin resistance (amp) gene 
and a plasmid origin of replication (Ori) flanked by the neomycin resistance (neo) 
gene in each long terminal repeat (LTR). Injection of these cells into C57Bl/6 
blastocysts at the McIntyre Transgenic Core Facility Service from McGill University 
(Montreal, Canada) resulted in chimeric mice that were bred with CD1 mice to 
attempt creation of a germline transmission of the Ptpa mutant allele. Progeny were 
weaned at day 21. A PCR genotyping strategy was used to differentiate between the 
mutant and wild-type alleles from DNA extracted from tail tips. A common forward 
primer was used alongside reverse primers specific to each allele. Primer sequences 
were: forward (10511F), 5′- GAGGCTGCGTTCTTTATGAGACTC-3′; mutant 
reverse (neoIN10), 5′-CAGGTCGGTCTTGACAAAAAGAAC-3′; and wild type 
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reverse (10511R), 5′- AAAAAGGAAGTGTGGTGGAAGGTAC-3′. These primers 
amplified bands of 442 nt and 477 nt for the mutant and wild-type allele, respectively.  
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4.5 RESULTS 
 
4.5.1 Reduction of PTPA by siRNA knockdown in HCT116 cells 
 
To determine whether human PTPA functions similarly to yeast Rrd1, we first 
sought to transiently knock down PTPA in cultured human cells. We first assessed 
the effectiveness of siRNAs derived from three separate regions of PTPA in the colon 
cancer cell line HCT116. Briefly, cells were transfected, RNA was recovered and 
subjected to RT-PCR with PTPA-specific oligos. As shown in Figure 4.1A, the 
siRNA construct B used at a concentration of 30 nm was the most effective to deplete 
mRNA level of PTPA with an efficiency of about 80% (quantification in Figure 
4.1B). We also monitored PTPA depletion at the protein level by Western blotting. 
PTPA was reduced by about 80% (quantification in Figure 4.1D) using the same 
siRNA construct B (Figure 4.1C). A FAM-labelled siRNA was used to monitor 
transfection efficiency and found that about 90% of the cells were transfected (Figure 
4.1E).  
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4.5.4 The growth defect in PTPA knockdown cells is p53-independent 
 
In order to better understand the cause of this growth defect, we decided to 
look at the expression level of key proteins involved in cell proliferation and 
apoptosis. Since it is known that inhibition of RNA pol II on chromatin leads to 
accumulation of p53 [15], we assessed p53 levels by Western blotting following 
PTPA knockdown.  p53 protein level was increased in the PTPA knockdown cells 
(Figure 4.4A). We also monitored the p21 (WAF1) level since its transcription is 
regulated by p53 [16]. p21 upregulation can lead to cell cycle arrest [17] which could 
explain the colony formation defect in the PTPA knockdown cells.  p21 was 
unchanged following PTPA knockdown, however excluding this pathway to explain 
the growth defect (Figure 4.4B).  
Since accumulation of p53 in mitochondria promotes apoptosis [18], we asked 
whether p53 accumulated in the mitochondria following PTPA knockdown. Cell 
fractionation was performed to obtain mitochondrial fractions, which were analyzed 
by Western blotting.  As shown in Figure 4.4F, cells knocked down for PTPA had 
more p53 protein in the cytosol and mitochondria, consistent with Figure 4.4A, but 
there was no accumulation in the mitochondria.   
Since PTPA knockdown led to an increase in p53 levels in both the cytosol 
and mitochondria, we next asked whether p53 depletion would rescue the PTPA 
growth defect.  We therefore knocked PTPA down in p53 -/- HCT116 cells and 
monitored colony formation. As shown in Figure 4.4G, both wild-type and p53 -/- 
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4.5.5 PTPA knockdown cells accumulate in G1 
 
In order to better define the growth defect in cells that have been depleted of 
PTPA, we chose to look at the cell cycle distribution. Cells were collected at different 
times following PTPA knockdown, dyed with propidium iodide (PI) and subjected to 
FACS analysis. Following PTPA knockdown, cells were delayed in G1 and did not 
progress through S phase as compared to control cells (Figure 4.5). Therefore, loss of 
PTPA causes a reduction in colony formation because the cells become arrested in 
G1. 
These results support a model in which loss of PTPA leads to RNA pol II 
accumulation on chromatin and increased p53 levels.  This leads to G1 arrest and 
decreased cell viability, although the colony formation defect is not p53-dependent. 
To further characterize the G1 arrest phenotype, we sought to follow the arrest to 
further time points and investigate activation of cell cycle checkpoints in PTPA-
deficient cells. To accomplish this, we attempted to create cell lines in which PTPA 
was stably knocked down.  A stable knockdown cell line would be useful for a 
variety of future studies and would avoid complications introduced by transient 
transfection of siRNA. 
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prepared and processed for Western blot analysis using anti-PTPA monoclonal 
antibody or Tubulin antibody as a loading control. These blots are representative of 
at least 3 different experiments. 
 
 
4.5.7 PTPA does not stably interact with other proteins and shows no evidence 
of post-translational modifications 
 
To gain further insight into the function of PTPA, we decided to hunt for 
PTPA-interacting partners using affinity capture. The PTPA crystal structure revealed 
a conserved pocket which could be a possible protein-protein interaction domain [8]. 
Dr. El Bachir Affar’s laboratory collaborated with us on this experiment.  
We first tagged PTPA with FLAG-HA in an overexpression vector. Because 
overexpression of PTPA in mammalian cells leads to apoptosis [10], we decided to 
mutate key amino acids that would suppress the pro-apoptotic activity of PTPA, but 
would be expected to retain interactions with potential partners. We used 3 different 
mutations (G205D, V209D and G290D) that have been previously shown to be 
catalytically inactive [8]. HeLa cells were transiently transfected with each of the 3 
mutants and wild-type PTPA and cell extracts were monitored for PTPA expression 
by Western blotting. As shown in Figure 4.8A, the cells transfected with the mutants 
expressed high levels of PTPA and grew normally (data not shown). On the other 
hand, overexpression of the wild-type PTPA killed most of the cells (data not shown) 
and made the collection of cell extracts difficult. Nonetheless, we were able to collect 
enough extract to perform a Western, which showed expression of tubulin (included 
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cells that had incorporated the plasmid. After 3 rounds of selection using the 
magnetic beads, stable clones were assayed for PTPA expression using 
immunofluorescence and western blotting. As shown in Figure 4.8B, the PTPA 
antibody was able to recognize both the FLAG-HA labelled protein and the 
endogenous PTPA level. Surprisingly, we were able to create stable clones 
overexpressing wild-type FLAG-HA-hPTPA protein, although these cells expressed 
low levels of PTPA, which likely explains how they were able to survive. We chose 
to continue the purification using only the FLAG-HA-hPTPA wild-type construct, 
since using a wild-type protein is more likely to identify true interacting partners.   
To identify potential complexes, we conducted a large-scale double 
immunopurification of the protein using anti-Flag and anti-HA columns. 
Unfortunately, silver staining of the eluted material revealed that no polypeptides 
copurified with PTPA when compared to the mock purification (Figure 4.9). 
Although there is a distinct band under PTPA, Western blotting revealed that this was 
a PTPA degradation product (data not shown). 
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vector U3NeoSV1 integrated in the first intron of the PTPA allele were introduced 
into C57Bl/6 blastocysts. Chimeric mice were then mated with CD1 females and 
germline transmission was analyzed by PCR amplification (Figure 4.12A) with tail 
DNA from progeny.  
From a total of 21 chimeras (both males and females), all the males were 
mated at least 4 times with CD1 females. All progeny were tested, but germline 
transmission of the PTPA knockout allele was not detected. An example of the PCR 
result from the F1 progeny is shown in Figure 4.12B. We also tried mating three 
female chimeras with CD1 males but there was still no germline transmission to the 
progeny. One possible explanation for this result could be that PTPA knockout is 
dominant lethal in mouse. To test whether loss of PTPA leads to embryonic lethality, 
we monitored plugs of females every 24 hours in order to establish an approximate 
mating starting point. At day 12, we isolated and genotyped the embryos from each 
female. The embryos tested had wild type PTPA allele and all were alive in utero. 
We believe that there was a germline transmission problem and after breeding for 
about 8 months, this line of research was discontinued due to lack of success and 
funding constraints. 
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4.6 DISCUSSION 
 
We first attempted to study the role of PTPA in mammalian cells by using 
transient siRNA knockdown, and found that loss of PTPA led to a growth defect 
caused by G1 arrest.  This result was not reproduced when PTPA was knocked down 
by shRNA, however.  In addition, we were unable to reproduce an rrd1Δ mutant-like 
phenotype with these cells. Since shRNA uses the endogenous processing machinery, 
their effect is more sustainable and use low copy number resulting in less off-target 
effect than with siRNA [19-21]. We believe that the growth defect could be an off-
target effect of siRNA. In the future, one could address this issue by using three 
different siRNA constructs to verify the phenotype and eliminate off-target effects. 
Another good option would have been to use a pool of siRNA instead of individual 
duplexes to analyze the effect of PTPA knockdown [28]. 
We believe there are multiple possible explanations for the differences 
observed between the yeast and mammalian results. The first potential problem with 
this work is the type of cells used for the knockdown. Since we do not know the 
function of PTPA in mammalian cells, it is challenging to choose the right cell line. 
We also noticed that PTPA is still expressed in the cells after the knockdown (Figure 
4.1 and 4.7) and we cannot exclude the possibility that a lower expression level is 
sufficient for PTPA to perform its function. Finally, we think that there could be 
another yet unidentified protein compensating for PTPA loss of function.  
As mentioned previously, using a pool of siRNA could have given us a better 
knockdown of PTPA and maybe a different phenotype. Ideally, the best option would 
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have been to create a knockout cell line in order to really avoid partial knockdown of 
PTPA. Nonetheless, we would still be facing the problem regarding the choice of cell 
line to study. So far, we believe that mouse embryonic fibroblast (MEF) would have 
been the best starting point. Finally, since deletion of both Rrd1 and Rrd2 is lethal in 
yeast [25] we do not know if complete deletion of PTPA in mammalian cells could 
also be lethal.  
 
 A possible key to understanding PTPA biological role is to identify proteins it 
isomerizes and looking for binding partners is a way to do it.  The affinity 
purification experiment did not identify any protein partners of PTPA. Surprisingly, 
we were unable to detect known interacting proteins such as PP2A subunits. In the 
future, this experiment could be repeated with less stringent parameters in order to 
confirm that known partners of PTPA are pulled down. We also think that PTPA 
could be interacting only transiently with other proteins and unfortunately the 
sensitivity of this method is not sufficient. Using nuclear or cytoplasmic extracts 
rather than whole cell extract could help to eliminate non-specific proteins. Finally, 
the last problem with this experiment is the low expression of FLAG-HA-PTPA 
protein in the cell (Figure 4.8B) reducing the chance of finding interacting partners. 
The catalytic mutants could be a good alternative to repeat the experiment, despite the 
caveat that the mutations could affect protein-protein interactions. A positive aspect 
of this analysis is that it shows that regulation of PTPA level in the cell is important 
for its survival which is consistent with previous work by our lab [10]. In other 
words, only the cells that were overexpressing the FLAG-HA-PTPA to a level 
comparable to the endogenous PTPA level were able to survive. 
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We then decided to study PTPA in mouse and choose to monitor the 
expression level of PTPA in various organs of the mouse (Figure 4.11).  We found 
that PTPA was highly expressed primarily in the bone marrow, the brain, the spleen 
and the thymus. We considered using T lymphocytes, but as shown in Figure 4.7, the 
DO11.1 cells were not a good model to perform siRNA studies. In this case, our best 
option was to create a knockout mouse and to derive cell lines from it. 
As described in the result section, we were unable to successfully create a 
knockout mouse for PTPA. It seems that the mutated allele was unable to go germline 
and create heterozygous progeny. Many factors seemed problematic in our 
methodology. First, it seems that the ES cell line that we were using is not ideal and 
an expert from the Sanger Institute recommended using the E14 ES cells instead of 
D3H. Another possibility is that the ES cells could have differentiated before their 
implantation in the foster female, preventing transmission of the mutation to the 
progeny.  Another explanation could be that deletion of one allele of PTPA is 
dominant lethal. Our observation that none of the live embryos carried the PTPA 
deletion supports this notion. Finally, it has been shown that Mycoplasma or viral 
contamination of ES cells can interfere with germline transmission [29, 30]. In the 
end, creation of the knockout mouse should be reattempted to address these issues. 
This could be done using a Cre/Lox construct allowing for conditional knockout in 
order to target specific organs or to avoid lethality during embryonic stages of 
development. Since PTPA is highly expressed in organs such as the thymus, the 
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spleen or the bone marrow (Figure 4.11), it would be relevant to start our 
investigation with them. 
 
Taken together, our results fell short in determining the biological function of 
PTPA in mammalian cells. Our studies in yeast revealed an important function for 
Rrd1 in regulating transcription in response to rapamycin or 4-NQO, and it is likely 
that PTPA functions in a similar capacity in mammalian cells. Future work 
addressing some of the technical limitations we encountered could lend more insight 
into this important biological question. 
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5 DISCUSSION 
 
PTPA is a highly conserved protein from yeast to humans and its expression is 
ubiquitous [87, 88, 90]. Deletion of both yeast homologs, RRD1 and RRD2, is lethal, 
revealing an important function for this gene in the cell [24]. PTPA was originally 
identified as an activator of PP2Ai but we have identified multiple additional roles in 
the cell [77, 110]. My thesis has focused on unravelling Rrd1/PTPA function using 
yeast and mammalian models. 
 
5.1 YEAST RRD1 
 
5.1.1 Rrd1 and RNA pol II 
 
The second chapter of my thesis focused on the role of Rrd1 in transcription in 
response to the immunosuppressant drug rapamycin. We showed that Rrd1 was 
bound to the chromatin in whole cell extract and co-immunoprecipitation assays 
revealed a weak interaction between RNA pol II and Rrd1 (Figure 2.1A and B). We 
also demonstrated that this interaction was present with or without rapamycin 
treatment (Figure 2.1B). Previous cellular localization studies showed that GFP-Rrd1 
was found in the cytoplasm and in the nucleus [23]. Moreover, our lab found that 
Rrd1 colocalizes on actively transcribed genes with RNA pol II in a recent genome-
wide location analysis study of RNA pol II on chromatin following rapamycin 
treatment [220]. These data support the idea that Rrd1 isomerizes RNA pol II while 
localized to the chromatin. The exact interacting domains between the two proteins 
remain to be found. Site-directed mutagenesis experiments and analysis of the 
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localisation of Rrd1 as well as its interaction with RNA pol II could provide insight 
into this. The CTD on RNA Pol II is the likely place where Rrd1 binds since the CTD 
is isomerized. Co-crystallisation of Rrd1 with RNA pol II peptides would be highly 
informative after the interacting domains are identified. Furthermore, it is still unclear 
how and under which conditions Rrd1 is recruited to the chromatin. A key question is 
why Rrd1 is recruited to some rapamycin-responsive genes and not others.  Maybe 
identifying Rrd1 interacting proteins would help identify the mechanism. 
Rrd1 was found to be a peptidyl prolyl cis/trans isomerase (PPIase), and prior 
to my work, its only known substrate was proline 190 of the PP2A catalytic subunit 
[88]. In this thesis, we showed that association of Rrd1 with RNA pol II allows 
isomerisation of the CTD of the large subunit Rpb1 following rapamycin or 4-NQO 
treatment (Figure 2.3B and 2.4). Circular dichroism experiments demonstrate a novel 
role for Rrd1 to induce this structural change both in vitro and in vivo (Figure 2.5B). 
The RNA pol II CTD is highly regulated by modifications such as phosphorylation, 
glycosylation and isomerisation and a plethora of factors interact throughout the 
transcription cycle. Ess1 in yeast (Pin1 in mammals) was already identified as an 
RNA pol II isomerase essential for the phosphatase Ssu72 to dephosphorylate the 
Serine 5 of the CTD [221]. Studies of Pin1 suggested that it recognized the 
phosphorylated CTD, and Pin1 overexpression led to transcription inhibition caused 
by dissociation of RNA pol II from the chromatin [135]. Our results suggest that a 
similar function is performed by Rrd1. However, the exact mechanism leading to the 
induction of Rrd1 isomerase activity is still poorly understood. Rrd1 is constitutively 
bound to RNA pol II, but our CD analysis showed that the CTD is only isomerized 
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after rapamycin treatment (Figure 2.3B and Figure 2.4).  Therefore, Rrd1 must 
somehow be activated following stress conditions such as rapamycin or 4-NQO 
treatment. Unpublished yeast two-hybrid experiment from our lab revealed that Rrd1 
interacts with a molecular chaperone belonging to the DnaJ family, Apj1, but the 
exact connection between the two proteins is still unknown. Surprisingly, we also co-
immunoprecipitated this GFP-labelled chaperone with Rpb1 (Figure 2.1C). Further 
characterisation of a possible modification of Rrd1 by this chaperone would be 
interesting to investigate.  
Interestingly, the loss of Rrd1 does not change the global RNA pol II CTD 
phosphorylation pattern. The analysis presented in the second chapter using specific 
antibodies that recognize RNA pol II phosphorylation status revealed that the level of 
Serine 2 and 5 phosphorylation was the same in wild type and rrd1Δ mutant cells 
(Figure 2.2A and S2.2). However, recent findings from our lab demonstrate that Rrd1 
binds to the elongating RNA pol II and that the phosphorylation pattern changes in an 
rrd1Δ mutant at specific genes. ChIP-chip analysis for serine 5 and serine 2 
phosphorylation using wild type and rrd1Δ mutant treated or not with rapamycin was 
used [220]. It seems that we were unable to detect these modifications using a general 
western blot experiment (Figure 2.2A) since the overall phosphorylation level in the 
cell does not change, but phosphorylation status varies locally at certain genes [220].  
We showed that Rrd1 performs isomerisation of RNA pol II CTD following 
4-NQO treatment as well as rapamycin (Figure 2.3B and 2.4). But how do these two 
distinct drugs result in the same response? Rapamycin treatment mimics starvation 
conditions whereas 4-NQO induces bulky DNA lesions as well as oxidative stress. In 
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the first case, rapamycin induces a reorganisation of transcription in order to respond 
to stress conditions. Ribosomal genes are inactivated to reduce translation and stress 
responsive genes are activated to counteract the effect of poor nitrogen sources [26, 
56]. Our chromatin immunoprecipitation (ChIP) results suggest that in an rrd1Δ 
mutant strain, the cells do not arrest because of a defect in transcriptional 
reorganisation caused by the lack of RNA pol II isomerisation (Figure 2.6). We 
believe that a similar pattern occur following 4-NQO treatment where stress 
responsive genes are not activated in an rrd1Δ mutant strain leading to accumulation 
of genotoxic stress [222]. Oxidative stress level measurement with a superoxide 
anion-sensitive probe, dihydroethidium, revealed that rrd1Δ mutant cells exhibit 
elevated levels of superoxide anions which could explain sensitivity of these mutants 
to 4-NQO [223].  Sensitivity of rrd1Δ mutant cells to other oxidizing agents such as 
H2O2 and sodium arsenite (NaAs) was also shown in later experiments. Moreover, 
analysis of mRNA using GeXP multiplex PCR system from wild type and rrd1Δ 
mutant strains treated or not with rapamycin, H2O2 or NaAs revealed the importance 
of Rrd1 in transcriptional stress responses [220]. On the other hand, methyl methane 
sulfonate (MMS) treatment, which causes apurinic/apyrimidinic sites on DNA, did 
not induce RNA pol II isomerisation and rrd1Δ mutant cells showed parental 
sensitivity to this agent [22]. Taken together, these results indicate that Rrd1 
responsiveness is highly specific to certain conditions and suggest additional levels of 
regulation via upstream factors.  
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5.1.2 RNA pol II loss 
 
 In chapter 3, we showed that total RNA pol II protein level decreased 
following extended rapamycin treatment in a wild type strain and that this loss was 
defective in an rrd1Δ mutant strain (Figure 3.1), confirming preliminary results [78]. 
The extensive analysis using different RNA pol II tag and yeast background showed 
accumulation of RNA pol II in an rrd1Δ mutant strain. Further characterisation of 
RNA pol II localisation revealed that the protein was still found in the chromatin 
extract in an rrd1Δ mutant strain whereas it was not visible in a wild type (Figure 
3.2A). Importantly, loss of RNA pol II protein in our extract was seen after 2 hours of 
treatment with rapamycin, but previous analysis in the literature studied RNA pol II 
distribution only after 30 minutes [56]. Even though global RNA pol II degradation 
does not occur until later, ChIP on chip experiments performed by our lab at 30 
minutes demonstrated a RNA pol II redistribution defect in the rrd1Δ mutant on 
rapamycin responsive genes [220]. Therefore, Rrd1 plays both early and late roles in 
the transcriptional response to rapamycin.   
We demonstrate that loss of RNA pol II is independent of ubiquitylation, 
revealing the existence of a novel degradation mechanism. We did not see differences 
between the wild type and the rrd1 mutant strain following analysis of the overall 
ubiquitylation status of co-immunuprecipitated RNA pol II (Figure 3.3A and B). 
Indeed, site-directed mutagenesis of the 2 lysine residues on Rpb1 that could be 
ubiquitylation targets did not prevent RNA pol II loss after rapamycin treatment 
(Figure 3.3C and D). Moreover, RNA pol II was still degraded even in a strain 
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lacking Elc1 (Figure 3.3E), a component of the ubiquitin ligase complex and 
important for polyubiquitylation of RNA pol II following DNA damage [224]. It 
would be interesting to look for other modifications such as sumoylation or 
acetylation of RNA pol II to get more insight into a possible mechanism. 
 
5.1.3 Rrd1 and TOR 
 
We showed in chapter 2 that rrd1Δ gln3Δ double mutants were highly 
resistant to rapamycin as compared to the single mutants, suggesting an independent 
role for Rrd1 in the rapamycin response (Figure S2.1). Dephosphorylation by Sit4 of 
the nutrient-responsive transcriptional activator Gln3 allows translocation to the 
nucleus to activate GLN1 and MEP2 expression [57, 225]. Rrd1 is part of the Tap42 
complex and interacts with Sit4 phosphatase and it is still unclear how this interaction 
affects the rapamycin response [23, 60]. Genetic studies revealed that both Rrd1 and 
Sit4 function in the same pathway to mediate protection against oxidative stress 
induced by 4-NQO, but rapamycin was not studied [23]. It is noteworthy to mention 
that GFP-Sit4 also interacts with Rpb1 (Figure 2.1C) which could mean that the 
interaction with this phosphatase plays a role in Rrd1 regulation and activity. We did 
not study this aspect in our analysis, but it would be interesting to investigate further 
the link between both proteins.  
 
5.1.4 Model 
 
Based on our results collected from these two papers, we propose the following 
model. When yeast cells are challenged with rapamycin or 4-NQO, Rrd1 bound to 
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transcribing RNA pol II becomes activated and induces the isomerisation of its CTD. 
Whether this occurs via the same upstream mechanism is unclear. In the case of 4-
NQO treatment it could be induced by accumulation of oxidative stress and activation 
of the transcriptional stress response, whereas with rapamycin it would involves 
starvation conditions resulting in a transcriptional reorganization. This CTD structural 
change allows RNA pol II to interrupt transcription of specific genes and leave the 
chromatin in order to be recruited to stress responsive genes in both cases. This 
dynamic process occurs after the first 30 minutes of rapamycin treatment, and 
extended time in the presence of the drug eventually leads to degradation of excessive 
RNA pol II independent of ubiquitylation. A schematic representation of our model is 
shown in Figure 5.1.  
  
Figure 5.
 
 
 
 
1: Proposed model of Rrd1 activity on RNA pol II  
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5.2 PTPA IN MAMMALIAN 
5.2.1 PTPA knockdown 
 
The results found in yeast and the high conservation of the RRD1 gene amongst 
species led us to hypothesize that a mammalian PTPA would perform similar 
functions. The last chapter on my thesis focused on understanding the role of PTPA 
in mammals using RNAi and mouse genetics.  
We first noticed that transient siRNA knockdown of PTPA led to a growth 
defect caused by G1 arrest. However, this result was not reproduced when PTPA was 
knocked down by shRNA and we believe that the growth defect could be an off-
target effect of siRNA. Indeed, our results using shRNA revealed that PTPA 
knockdown did not affect the general survival of several cell lines. Additionally, 
PTPA knockdown HCT116 cells did not show sensitivity to 4-NQO, H2O2 or 
resistance to rapamycin (Figure 4.6). One possible explanation for this difference 
could be that the knockdown was not 100% efficient. Residual activity of the PTPA 
protein or compensation by an unidentified protein could be sufficient to prevent 
detection of a phenotype. Our analysis also revealed that PTPA overexpression leads 
to cell death (Figure 4.8) and that only cells expressing low PTPA survived [122]. 
This suggests that only a small amount of the protein is required for cell homeostasis.  
A possible alternative approach for studying PTPA knockdown and establish a 
parallel with our yeast work, could be to choose a different cell line. Studies using 
cells from the knockout mouse, assuming it is not lethal, would be another option. At 
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last, the chicken B cell line DT40 represents another alternative since it allows 
efficient gene disruption [226].  
PTPA knockdown analysis in HEK TER cells showed that PTPA is involved in 
the regulation of PP2A methylation leading to cell transformation [121]. This study 
revealed a new role for PTPA as a possible tumor suppressor gene and it would be 
interesting to check if this mechanism is also present in other cell lines. Since we 
found that PTPA was highly expressed in some mice organs such as the brain, the 
thymus or the bone marrow (Figure 4.11), it would be interesting to start with these 
cell lines. 
 
5.2.2 PTPA substrates 
 
We also attempted to isolate PTPA binding proteins by affinity purification in 
order to identify new possible targets for its PPIase activity. This first and only 
analysis where we used whole cell extract did not identify any stable partners for 
PTPA (Figure 4.9). Moreover, our assay did not isolate known interacting partners 
such as Pph3 or CCT complex proteins (Figure 4.10) found by another group [119]. 
This indicates that our pulldown conditions may have been too stringent.  Using 
nuclear or cytoplasmic extracts rather than whole cell extract could help to eliminate 
non-specific proteins. We also believe that reducing the concentration of salt in the 
washes could increase our chance of finding partners that are not tightly bound. 
Finally, it is possible that PTPA only interacts transiently with its substrates making it 
difficult to detect these interactions by affinity capture. Several other techniques can 
be used to detect transient interactions, such as nuclear magnetic resonance (NMR) 
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[227] or fluorescence resonance energy transfer (FRET) [228], but these methods are 
not suitable for exploratory or screening-type applications [229]. The yeast two-
hybrid system could also be a possible alternative. Our lab previously used Rrd1 as 
bait in Y2H and found that Apj1 could be a possible partner (unpublished data) and 
we believe that performing the same experiment using PTPA as a bait could identify 
new partners or substrates. 
 
5.2.3 PTPA in mice 
 
To better study the importance of PTPA in mice, we successfully generated 
chimeras from ES cells lines obtained from the International Gene Trap Consortium 
[230]. Unfortunately, we were unable to get germline transmission of the mutated 
allele to the progeny after breeding the chimeras for several rounds (Figure 4.12). We 
therefore asked whether PTPA heterozygosity could cause lethality. Indeed, the 
embryos at day 12 were all healthy and none of them carried the mutated allele. We 
believe that PTPA performs an important function in mammals and we cannot 
exclude the possibility that deletion of one allele causes lethality, especially given 
that deletion of both Rrd1 and Rrd2 in yeast is lethal.  
The other possible complication could reside in the ES cells. It was shown that 
viral or Mycoplasma contaminations of ES cells can interfere with germline 
transmission and no such analysis were performed. Moreover, an expert from the 
Sanger Institute recommended using E14 ES cells instead of D3H to increase our 
success rate. The lack of funding resources led us to prematurely abort the project 
without further investigation. 
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In the future, a better alternative would be to create a conditional Cre-Lox 
knockout mouse in which a tissue-specific promoter induces expression of the Cre 
recombinase, deleting PTPA in that tissue only [231]. For example, it would be 
interesting to use tissue-specific promoter for the knockout in thymus, bone marrow 
or brain since PTPA expression is higher in those organs.   
 
5.3 CONCLUSION 
 
Taken together, our data suggest that Rrd1 participates in a novel mechanism 
that allows redistribution of RNA pol II for transcriptional regulation of genes 
involved in specific stress conditions. Indeed, Rrd1 interacts and isomerises RNA pol 
II and promote its dissociation from the chromatin. Furthermore, we showed that 
sustained treatment with rapamycin induces RNA pol II degradation in an 
ubiquitylation-independent pathway.  
Our investigation in mammals did not allow us to define a model for PTPA 
function. Unfortunately, we were unable to reproduce an rrd1Δ mutant-like 
phenotype in mammalian cells. Moreover, the affinity purification experiment did not 
identify any protein partners of PTPA. Finally, we were unable to successfully create 
a knockout mouse for PTPA. But as mentioned previously, the high homology 
between the yeast and mammalian sequences and the conservation between species 
suggest an important role for PTPA in mammals. Indeed, our results in yeast could 
indicate that PTPA performs a possible similar function in mammalian cells in 
regulating transcription in response to specific stress. We still believe that we are very 
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close of discovering a related function of PTPA in mammals and finding a good 
model system will highly increase the chances of identifying its function in the cell. 
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